



ACCELERATING THERAPEUTICS:

Innovation, Integration, and Impact.



27TH ANNUAL BIOPACIFIC CONFERENCE
SOUTH SAN FRANCISCO CONFERENCE CENTER

TABLE OF CONTENTS

Sponsors ➤01

CABS Mission Statements ➤03

About CABS ➤04

Remarks ➤05

2026 CABS Leadership ➤07

2026 BioPacific Conference Organizing Committee ➤09

2025 CABS Service Awards ➤11

Conference Floor Plan ➤13

Conference Agenda ➤15

2026 CABS K. Fong Award ➤17

BioPac Conference Speakers ➤21

BioPac Conference Panelists ➤24

Lunch Break & Noon Session ➤28

Session Chairs Team ➤29

Science & Technology Poster Session ➤30

2025-2026 Selected CABS Activities ➤31

BioPac Conference Sponsors’ Ads ➤43

PROGRAM BOOK
PRODUCTION

CHIEF EDITOR
Liang He

For Fundraising
Fundraising@CABSweb.org

EDITORS
Liping Meng
Sihong Zhou
Shicheng Guo
Zhiqing Wang
Yanan Wang
Vivian Liu
Lu Lu

For Membership
Membership@CABSweb.org

GRAPHIC DESIGNER
Elva Huang

General Information
Info@CABSweb.org

SPECIAL THANKS TO OUR SPONSORS

Long-Term Partner




Diamond

Keting Chu

Platinum



Gold



Silver



Exhibitor



Media Partners



OUR VISION

To serve as the gateway linking life science professionals & organizations in the U.S. & Pacific Rim Countries.

OUR MISSION


- To SERVE life science professionals to promote professional interactions locally and across the Pacific.
- To FOSTER business opportunities and exchanges in the life science industry between the U.S. and Pacific Rim countries.
- To PROMOTE public awareness of progress and development in the life sciences industry.
- To COLLABORATE with other organizations in areas of mutual interest.

CHINESE AMERICAN BIO/PHARMACEUTICAL SOCIETY (CABS)

The Chinese American Bio/Pharmaceutical Society (CABS) is a non-profit organization for professionals in the biopharmaceutical industry. CABS is headquartered in the San Francisco Bay Area, California. This is the home of Silicon Valley, the birthplace of biotechnology and one of the largest biomedical clusters with the highest venture capital investment in the world. There are more than a thousand biopharmaceutical/biotech companies in this area, including several large biopharmaceutical companies such as Amgen, Genentech and Gilead. CABS is a highly influential association with more than 3000 members and 20000 subscribers in the life sciences industry. About 70% of our members have PhD degrees relating to life sciences.

A considerable proportion of the members hold senior research and management positions in US-based and multi-national life sciences corporations. Many of our members are experts and leaders, innovative entrepreneurs, lawyers and venture capitalists, or investors in the life sciences sector. CABS is one of North America's most active largest biopharmaceutical associations. We organize many activities to promote international collaborations in life sciences. In addition to year-round technology and business seminars, the annual BioPacific Conference organized by CABS is a highly anticipated event that attracts hundreds of biopharmaceutical professionals and business leaders.

- Founded in 1998, a volunteer-based, non-profit organization for professionals in life sciences.
- Headquartered in the San Francisco Bay Area.
- 3,000+ members and 20,000+ subscribers in 30+ countries.



REMARKS FROM

PRESIDENT OF CHINESE AMERICAN BIO/ PHARMACEUTICAL SOCIETY(CABS)

Dear CABS members, distinguished speakers, sponsors, partners, volunteers, and friends,

On behalf of the Chinese American Bio/Pharmaceutical Society, it is my great pleasure to welcome you to the 2026 BioPacific Conference, the 27th annual conference.

As CABS's annual flagship event, the BioPacific Conference brings together leaders from academia, the biopharmaceutical industry, healthcare, investment, and entrepreneurship. It provides a valuable platform for sharing scientific advances, exchanging perspectives, building meaningful partnerships, and exploring new opportunities across the Pacific Rim.

Building on the success of the 2025 BioPacific Conference, we are delighted to gather once again for an inspiring day of scientific exchange and professional connection. I was honored to serve last year as CABS President-Elect and Chair of the Conference Organizing Committee, and I am deeply grateful for the opportunity to continue serving our community as President this year.

The life sciences industry is undergoing rapid transformation. Advances in artificial intelligence, genomic medicine, precision diagnostics, data science, and novel therapeutic platforms are reshaping how we understand disease and develop new medicines. At the same time, our industry continues to face challenges in funding, regulation, global competition, and translating promising discoveries into meaningful benefits for patients.

This year's BioPacific Conference reflects both these opportunities and challenges. We are honored to welcome distinguished speakers, panelists, innovators, and industry leaders who will share their knowledge,

perspectives, and experience. We are especially privileged to welcome Nobel laureate Dr. Randy Schekman and Dr. Joseph C. Wu as featured speakers in this year's K. Fong Award program. Their achievements exemplify scientific excellence, visionary leadership, and a lasting commitment to improving human health.

CABS's work extends far beyond this annual conference. Throughout 2026, we have continued to serve the life sciences community through scientific workshops, investor and entrepreneurship forums, career development and mentorship programs, and initiatives supporting students and emerging professionals. These programs have addressed topics ranging from genetic medicine and industry innovation to career advancement, cross-sector collaboration, and emerging applications of artificial intelligence and data science.

This year, we also established the Information Technology and Data Science Committee, bringing the total number of CABS committees to nine and strengthening our ability to respond to the rapidly evolving role of technology in drug discovery and healthcare. Alongside these professional programs, our Chinese New Year Gala, Dragon Boat Race, and other social gatherings have fostered friendship, strengthened connections, and contributed to a vibrant and supportive CABS community.

These efforts reflect the broader mission of CABS: to serve life science professionals, foster business opportunities and exchanges between the United States and the Pacific Rim, promote awareness of advances in the life sciences, and collaborate with organizations that share our commitment to innovation and public benefit. As our industry continues to evolve, CABS remains committed to serving as a bridge across disciplines, sectors, communities, and regions.

None of this would be possible without our volunteers. My sincere thanks to President-Elect Dr. Liping Meng, the Conference Organizing Committee, the CABS Executive Council, our nine committees, and everyone who has contributed their time, energy, and expertise.

I also extend my heartfelt appreciation to our speakers, panelists, sponsors, exhibitors, partners, supporters, and attendees. Your participation makes this conference possible and strengthens the CABS community. I encourage you to take full advantage of today's program to learn, connect, exchange ideas, and build new collaborations.

Welcome to the 2026 BioPacific Conference. I hope you have an inspiring, productive, and memorable experience.

Warm regards,

Sihong Zhou

President of CABS | 2026



WELCOME TO THE 2026 BIOPACIFIC CONFERENCE

It is my great honor to serve as President-Elect of the Chinese American Bio/Pharmaceutical Society (CABS) and Chair of the 2026 BioPacific Conference Organizing Committee. On behalf of CABS, I warmly welcome you to the 27th Annual BioPacific Conference.

For more than two decades, the BioPacific Conference has been a premier forum for scientific exchange, professional development, and collaboration across the global life sciences community. What began as a regional gathering has grown into a highly anticipated annual event connecting leading scientists, healthcare innovators, entrepreneurs, investors, and industry executives from around the world.

This year's theme, "**Accelerating Therapeutics: Innovation, Integration, and Impact**," reflects both the extraordinary opportunities and challenges facing our industry. Advances in artificial intelligence, genomics, cell and gene therapies, precision medicine, and data science are transforming biomedical research at an unprecedented pace. Translating these discoveries into meaningful patient outcomes requires collaboration across disciplines, strategic partnerships, and innovative approaches to accelerate the development of life-changing therapies.

We are honored to present the **2026 K. Fong Award in Life Sciences** to **Dr. Randy Schekman** and **Dr. Joseph C. Wu**. Nobel Laureate Dr. Schekman, Professor at the University of California, Berkeley, is internationally recognized for his pioneering discoveries in cellular membrane trafficking that transformed modern cell biology. Dr. Wu, Director of the Stanford Cardiovascular Institute, is a global leader with groundbreaking work in precision medicine and "clinical trials in a dish" continues to reshape the future of drug development and patient care.

The conference features distinguished keynote speakers who will offer perspectives spanning therapeutic innovation, scientific discovery, and entrepreneurship. **Dr. Flavius Martin**, Executive Vice President of Research at Gilead, and **Dr. Jan Smith**, Chief Scientific Officer at Revolution Medicines, will highlight emerging therapeutic strategies—from understanding shared pathogenic mechanisms across diseases to advancing orally bioavailable RAS(ON) inhibitors designed to overcome resistance in RAS-driven cancers. **Dr. Keting Chu**, Founder and former CEO of Bluejay Therapeutics, and **Dr. Yuling Luo**, Founder and CEO of Alamar Biosciences, will share complementary perspectives on translating scientific innovation into impact, including building a successful biotechnology company from an early-stage startup and advancing precision proteomics for earlier disease detection and translational research.

Three expert panel discussions will bring together leaders from academia, biotechnology, pharmaceutical companies, and venture capital to discuss AI in drug discovery, strategies for successful biotechnology companies and partnerships, and the evolving investment landscape for emerging biotech. These sessions will inspire collaboration, new ideas, and practical perspectives on the future of our industry.

The success of the BioPacific Conference is made possible by the dedication and generosity of our speakers, sponsors, exhibitors, volunteers, Organizing Committee, and CABS leadership. I sincerely thank each of them for their invaluable contributions.

Most importantly, thank you to all attendees for joining us. Your passion for science, innovation, and collaboration makes this community vibrant and impactful. I encourage you to take full advantage of the scientific sessions, panel discussions, exhibitions, and networking opportunities throughout the conference. Together, we can build partnerships, inspire innovation, and accelerate the development of therapies that improve and save lives.

I wish you an inspiring, productive, and rewarding conference.

Sincerely,

Liping Meng

PhD | President-Elect of CABS | 2026



2026 CABS LEADERSHIP

2026 EXECUTIVE COUNCIL Office of the President



PRESIDENT
Sihong Zhou
Senior Scientist, Sutro Biopharma



PRESIDENT-ELECT
Liping Meng
PhD; Principal Scientist II, Gilead Sciences



PAST PRESIDENT
Kay Tong
MA; CEO, N2N GXPS4U

BOARD OF DIRECTORS



Sihong Zhou
Senior Scientist
Sutro Biopharma



Kay Tong
MA; CEO, N2N GXPS4U



Wentao Zhang
PhD; Co-CEO of Frontage
Laboratories, Inc



Zhonghua Pei
PhD; Senior Vice President, Drug Discovery
at Lyterian Therapeutics



Yan Wang
PhD; Executive Director,
Lepu Biopharma



Cheni Kwok
PhD; CLP, Managing
Partner, Linear Dreams



Alex J. Zhang
PhD; Founder & CEO,
OneTwenty Therapeutics



Yuying "Kate" You
PhD, JD; Patent Attorney,
Morrison Foerster LLP



Janet Xiao
PhD, JD; Partner,
Morrison Foerster LLP



Jing-Shan "Jennifer" Hu
PhD; Former Senior Advisor & Founding
Partner, Qiming U.S. Healthcare Fund



John Wang
PhD; Founder and CEO,
IOVaxis Therapeutics

OFFICE OF OPERATIONS (O2)

- Co-Chair: **Liang He**, PhD, Scientist, Frontage; **Katherine Guan**, Scientist II, AbbVie.
- Member: **Baixue Doris Zhang**, AI Engineer Intern, Venera AI.

MEMBERSHIP COMMITTEE (MEM)

- Co-Chair: **Amy Yang**, Scientist, Bayer.
- Advisor: **Bing (Vivian) Liu**, Director, Novogene.
- Member: **Dan Su**, Postdoc, Stanford; **Lillian Jiang**, BD Manager, iHealth Labs.

PUBLIC RELATIONS & COMMUNICATIONS COMMITTEE (PRC)

- Co-Chair: **Bing (Vivian) Liu**, Director, Novogene; **Zhiqing Wang**, PhD, Scientist, 10x Genomics.
- Advisor: **Shicheng Guo**, Senior Director, Arrowhead.
- Member: **Lillian Jiang**, BD Manager, iHealth Labs; **Lingling Peng**, PhD, Scientist, Genentech; **Boting Li**, PhD Candidate, McGill University.

ALLIANCE MANAGEMENT COMMITTEE (AMC)

- Co-Chair: **Yanan Wang**, PhD, Senior Scientist, QLSF Biotherapeutics; **Le Cai**, PhD, Scientist, A&P Inphatec.
- Member: **Lingling Peng**, PhD, Scientist, Genentech; **Lijuan (Jenny) Wang**, PhD, Chief Clinical and Regulatory Officer, Almach Bio; **Yinan Lin**, PhD, Life Sciences Transactions Attorney, Dickinson Wright.

SCIENCE & TECHNOLOGY COMMITTEE (STC)

- Co-Chair: **Alex Yang**, PhD, Senior Scientist, Vir Biotechnology; **Lin Wang**, Director, Gilead.
- Member: **Mengning "Frank" Zhou**, PhD, ChFC®, CLU® Financial Planner, MassMutual Financial Group; **Wenhui Guo**, Postdoc, Stanford; **Zheng Cai**, Volunteer.

INTERNATIONAL COLLABORATION COMMITTEE (ICC)

- Co-Chair: **Yu Yang**, MS, CEO, Hanhai Silicon Valley Center; **Guanghui Han**, PhD, General Manager Proteomics Novogene Corporation Inc.
- Member: **Lingling Peng**, Scientist, Genentech; **Tim Tian**, Independent Consultant.

BUSINESS & CAREER DEVELOPMENT COMMITTEE (BCD)

- Co-Chair: **Wenjia Gu**, PhD, Scientist, Sutro Biopharma; **Yan Wang**, PhD, Director, Analytical Chemistry, Vilya Therapeutics.
- Advisor: **Guanghui Han**, PhD, General Manager Proteomics Novogene Corporation Inc.
- Members: **Chunling Wang**, PhD, Staff Scientist, Thermo Fisher Scientific; **Tiffany Shang**, Director, Allakos; **Lin Song Kretschmer**, PhD, Scientist, UCSF.
- E-Club Co-Chair: **Lu Lu**, MS, Associate Director, Eli Lilly; **Denna Kwang**, Account Manager, ABclonal Technology.
- E-Club Advisor: **Jack Zhu**, MBA, Associate Director, Market Access Analytics, Rigel Pharmaceuticals.
- E-Club Member: **Huijun Zhou**, PhD, Adjunct Professor, Stanford University; **Weibin Zheng**, BD Manager, Vazyme Biotech; **Yujiao Zhang**, PhD, BD Manager, Kactus.
- CAN Co-Chair: **Jonathan Wong**, Founder, Enigma Search; **Feng Pan**, PhD, President/Co-Founder, LexigenBio.
- CAN Member: **Chunling Wang**, PhD, Former Staff Scientist, Thermo Fisher Scientific; **Tiffany Shang**, Head of Medical Affairs Operations, Annexon Biosciences.

SOCIAL LIFE COMMITTEE (SLC)

- Co-Chair: **Li Wang**, Manager, Arcus Biosciences; **Crystal Tan**, MS, Nurse at Ophthalmology, San Francisco General Hospital.
- Member: **Xinxin Li**, MS, VP, MyBioGate; **Mingdian Tan**, PhD, Postdoc, Stanford University; **Yuki Yang**, Research Associate II - Vaxart Inc; **Lingling Peng**, Scientist, Genentech; **Will Chou**, MD, JD; **Hailun Wan**, BD Manager, HitChem.

IT & DATA SCIENCE (ITDS)

- Co-Chairs: **Shicheng Guo**, PhD, Senior Director, Arrowhead Pharmaceuticals; **Zuolin Cheng**, Postdoctoral Scholar, Stanford University
- EC Member: **Zhuoqing Fang**, Research Engineer, Stanford; **Katherine Guan**, Scientist II, AbbVie; **Baixue Doris Zhang**, AI Engineer Intern, Venera AI
- Member: **Le Cai**, **Lena Li**, **Yi Zhong**, **Lucy Liu**, **Malina Qin**, **Ying Yang**, **Zhiqing Wang**, **Elva Huang**

ACCOUNTANT

- Yao Long**

ORGANIZING COMMITTEE

- Liping Meng, PhD**
President-Elect, CABS; Principal Scientist II, Gilead Sciences
- Sihong Zhou**
President CABS; Senior Scientist, Sutro Biopharma
- Liang He, PhD**
Scientist, Frontage
- Shicheng Guo, PhD**
Senior Director, Arrowhead Pharmaceuticals
- Yan Wang, PhD**
Senior Director, Peptide Chemistry, Stealth Mode Biotech
- Zhiqing Wang, PhD**
Senior Scientist, IOx Genomics
- Katherine Guan**
Scientist II, AbbVie
- Le Cai, PhD**
Scientist, A&P Inphatec
- Yanan Wang, PhD**
Senior Scientist, QLSF Biotherapeutics
- Wenjia Gu, PhD**
Scientist, Sutro Biopharma
- Bing “Vivian” Liu, PhD**
Director, Novogene

- Lifei “Alex” Yang, PhD**
Senior Scientist, Vir Biotechnology
- Lu Lu, MS**
Associate Director of External Partnering, Eli Lilly Explor&D
- Guanghui Han, PhD**
General Manager Proteomics Novogene Corporation Inc
- Amy Yang**
Scientist, Bayer
- Lin Wang, PhD**
Director, Gilead
- Mengning Zhou, PhD**
ChFC®, CLU® Financial Planner, MassMutual Financial Group
- Feng Pan, PhD**
President/Co-Founder, LexigenBio
- MINGDIAN TAN, PHD**
Postdoc, Stanford University
- DENNA KWANG**
Account Manager, ABclonal Technology
- CRYSTAL TAN, MS**
Nurse at Ophthalmology, San Francisco General Hospital
- BAIXUE DORIS ZHANG**
AI Engineer Intern, Venera AI



PROGRAM BOOK COMMITTEE

- Liang He, PhD**
Scientist, Frontage
- Liping Meng, PhD**
President-Elect, CABS; Principal Scientist II, Gilead Sciences
- Sihong Zhou, President**
CABS; Senior Scientist, Sutro Biopharma
- Shicheng Guo, PhD**
Senior Director, Arrowhead
- Zhiqing Wang, PhD**
Senior Scientist, IOx Genomics
- Yanan Wang, PhD**
Senior Scientist, QLSF Biotherapeutics
- Le Cai, PhD**
Scientist, A&P Inphatec
- Bing “Vivian” Liu, PhD**
Director, Novogene
- ELVA HUANG**





FIVE-YEAR EC SERVICE

THREE-YEAR EC SERVICE



Tim Tian
Volunteer



Yu Yang
ICC



Li Wang
SLC



Crystal Tan
SLC



Sylvia Lu
Volunteer



Mingdian Tan
SLC, AMC

EC CO-CHAIR LEADERSHIP SERVICE AWARD



Liang He
O2



Yanan Wang
AMC




Le Cai
AMC



Wenjia Gu
BCD



Yan Wang
BCD



Jonathan Wong
CAN



Feng Pan
CAN



Lu Lu
E-Club



Jack Zhu
E-Club



Yu Yang
CEO | Hanhai



Guanghui Han
ICC



Amy Yang
MEM



Vivian Liu
MEM



Shicheng Guo
PRC



Zhiqing Wang
PRC



Li Wang
SLC



Crystal Tan
SLC



Liping Meng
STC



Alex Yang
STC

OUTSTANDING CO-CHAIR AWARD



Shicheng Guo
PRC



Yanan Wang
AMC



Wenjia Gu
BCD

OUTSTANDING EC AWARD

OUTSTANDING VOLUNTEERS WHO HAVE DEMONSTRATED CABS' MISSION TO SERVE, FOSTER, PROMOTE AND COLLABORATE.



Katherine Guan
O2 | Serve



Zhiqing Wang
PRC | Serve



Mingdian Tan
AMC, SLC



Peng'an Liu
AMC



Denna Kwang
BCD, CAN, E-club | Serve




Jacky Zheng
STC, BCD | Promote



Zuolin Cheng
CAN | Promote



Yujiao Zhang
E-Club



Tim Tian
ICC



Lillian Jiang
PRC



Lin Song Kretschmer
PRC



Yuki Yang
SLC



Zheng (Jane) Cai
STC

2025 BIOPACIFIC CONFERENCE SPECIAL RECOGNITION



Vivian Liu
Team Leader of
Logistics & Moderator



Yanan Wang
Fund Raising &
Moderator



Shicheng Guo
Event Promotion &
Moderator



Zhiqing Wang
Designer



Wenjia Gu
Team Leader of
Logistics & Moderator



Liang He
Program Book &
Moderator



Amy Yang
Team Leader of
Registration



Lu Lu
Moderator



Le Cai
Team Leader of
AV System



Guanghui Han
Team Leader of
Photography

OUTSTANDING VOLUNTEER AWARD
PUBLIC RELATIONS COMMITTEE

Dr. Lena Li
Dr. Yi Zhong

Ms. Baixue Doris Zhang
Dr. Ying Yang

OUTSTANDING VOLUNTEER AWARD

SOCIAL LIFE COMMITTEE
Bonita Zhang

MEMBERSHIP COMMITTEE
Vicki Tan
Chih-liang Chin

CABS ORGANIZATION DEDICATED & DEPENDABLE VOLUNTEER
Su Dong Xinxin Li Zhuoqing Fang



2026



CABS

FLOOR PLAN

FLOOR PLAN

South San Francisco Conference Center
255 S Airport Blvd, South San Francisco, CA 94080

Cocktail Reception Room / L&L (Oyster Point)



AGENDA

08:45 AM – 08:50 AM

WELCOME

Liping Meng, PhD (President-elect of CABS and Organizing Committee Chair of 2026)

08:50 AM – 08:55 AM

STATE OF THE SOCIETY

Sihong Zhou (President of CABS)

MORNING SESSION 1

SESSION CHAIR - Mengning “Frank” Zhou (CABS STC EC member)

09:00 AM – 09:35 AM

KEYNOTE SPEECH - Flavius Martin (MD, PhD, EVP, Gilead Sciences)

Eliminating Pathogenic Mechanisms Across Virology, Oncology, and Inflammation

09:35 AM – 09:45 AM

2025 K. FONG AWARD IN LIFE SCIENCES

09:45 AM – 10:20 AM

K. FONG AWARD ACCEPTANCE SPEECH I - Randy Schekman (PhD, Professor, UC Berkeley)

Tackling Parkinson’s Disease with Basic Science

10:20 AM – 11:00 AM

COFFEE BREAK, VENDOR SHOW, POSTER PRESENTATION, NETWORKING

MORNING SESSION 2

SESSION CHAIR - Amy Yang (CABS MEM Co-chair)

11:00 AM – 11:35 AM

K. FONG AWARD ACCEPTANCE SPEECH II - Joseph C. Wu (MD, PhD, Professor, Stanford University)

New Approach Methodologies: From Genomic Medicine to Clinical Trial in Dish

11:35 AM – 12:15 PM

PANEL ONE

Designing for Success: Startup Strategy, Partnership, and Inflection Points

MODERATOR	LU LU	CABS E-Club Co-chair; Associate Director of External Partnering, Eli Lilly ExploR&D
PANELIST	JIMMY ZHANG, PhD, MBA	Operating Advisor, Blackstone; Executive Mentor, QB3/Bakar Labs, UC Berkeley
	JAIONE MAIZ, PhD, MBA	Senior Director, External Partnering, Eli Lilly ExploR&D
	WENWU ZHAI, MD, PhD	Chief Scientific Officer and R&D General Manager, HanchorBio Inc
	JONATHAN NORRIS, JD	Managing Director, HSBC Innovation

12:15 PM – 01:50 PM

LUNCH BREAK & NOON SESSION - Le Cai, CABS AMC Co-chair

(Location: Oyster Point)

12:15 PM – 12:45 PM	Platinum Sponsor Presentation Scaling Biomanufacturing to 20,000L: A Large-Scale mAb Production Case with High Titer, High Yield, and High-Concentration Formulation Presenter: Rubin Jiang, Senior Director, Manufacturing, Science and Technology at Altruist Biologics
12:45 PM – 01:05 PM	Platinum Sponsor Presentation - Presenter: Apeloa
01:05 PM – 01:20 PM	Gold Sponsor Presentation - Presenter: GatorBio

01:20 PM – 01:35 PM

Gold Sponsor Presentation

Organ-on-a-Chip: Core Platform for Next-Generation Preclinical Drug Evaluation
Presenter: Xiaoming Hong, Chairman at Harbios

01:35 PM – 01:50 PM

Gold Sponsor Presentation

Accelerating drug discovery through partnership with CRO
Presenter: Mingfeng Bai, SVP at Medicilon

AFTERNOON SESSION 1

SESSION CHAIR - Shicheng Guo (CABS ITDS Co-chair, PRC Advisor)

01:50 PM – 02:25 PM

KEYNOTE SPEECH - Jan Smith (PhD, CSO, Revolution Medicines)

Targeting the Oncogenic State of RAS with Tricomplex Inhibitors

02:25 PM – 03:05 PM

PANEL TWO

Toward the Tantalizing Goal of AI-enabled Drug Discovery and Development

MODERATOR	ZHONGHUA PEI, PhD	Senior Vice President of Drug Discovery, Lyterian Therapeutics
PANELIST	JAMES ZOU, PhD	Associate Professor of Biomedical Data Science, Stanford University; Director, Stanford AI for Science Lab
	CHRIS FOTI, PhD	Senior Director, Analytical Development, Gilead Sciences
	KAREN (YITONG) HE	Associate Director, Global Business Development, CosynBio

03:05 PM – 03:35 PM

COFFEE BREAK, VENDOR SHOW, POSTER PRESENTATION, NETWORKING

AFTERNOON SESSION 2

SESSION CHAIR - Yanan Wang (CABS AMC Co-chair)

03:35 PM – 04:10 PM

KEYNOTE SPEECH - Keting Chu (MD, PhD, Ex-Founder and CEO, Bluejay Therapeutics)

The Bluejay Story

04:10 PM – 04:45 PM

KEYNOTE SPEECH - Yuling Luo (PhD, Founder and CEO, Alamar Biosciences)

Powering Precision Proteomics to Enable the Earliest Detection of Disease

04:45 PM – 05:25 PM

PANEL THREE

Cracking the Code: What Attracts Venture Capital in Biotech

MODERATOR	JING-SHAN "JENNIFER" HU, PhD	Former Partner and Senior Advisor, Qiming Venture Partners USA
PANELIST	CHEN YU, MD, MBA	Founder and Managing Partner, TCGx
	JUDITH J. LI, MBA, JD	Partner, Lilly Asia Ventures
	LUPING HUANG, MD, PhD	Chief Business Officer, Fosun Health Capital (Member of Fosun Pharma Group)
	LISA SILVERMAN, PhD, JD	Partner, Morrison Foerster; Firm’s Venture Intellectual Property Group

05:25 PM – 05:30 PM

CLOSING REMARK - Sihong Zhou, Liping Meng

EVENING RECEPTION

SESSION CHAIR - Wenjia Gu (CABS BCD Co-chair) & Liang He (CABS O2 Co-chair)

05:30 PM –07:45 PM

EVENING NETWORKING RECEPTION, FOOD STATIONS

(Location: Oyster Point)

About

KENNETH FONG

Dr. Kenneth Fong has spent the last 42 years in the biotech industry after completing his academic pursuit in biomedical research.

Dr. Kenneth Fong is best known for founding the biotech company, Clontech in 1984 which he built into one of the largest biomedical tool companies founded by an Asian American in the US (400 employees including 65 PhD scientists). Clontech was acquired by Becton Dickinson in 1999 and Ken has continued his career as a Venture capitalist with Kenson Ventures that he founded. He has since cultivated 12 highly successful entrepreneurs, advising them and working with them on the growth of their companies.

Currently, he sits on the board of 4 biotech companies and he was intimately involved with the M/A and IPO of more than 15 companies that are worth more than \$7 billion. These companies range from research tools, medical diagnostics and drug development. In almost all cases, Dr. Fong has been instrumental in providing strategies for sustainable growth, value creation and liquidity. Those successful entrepreneurs have moved on to assume leadership in other start-up and mid-sized companies, which in turn led to a new generation of entrepreneurs.

Ken has held a number of leadership positions over the years. He served as the President of the Society of Chinese Bioscientists in North America (2006-2007) and President of the Bay Area Asian American Manufacturers' Association (AAMA, 1987). He was also a member of the Board of Trustees of the California State University System (2006-2013). His philanthropic interests include scholarships to San Francisco State University, the Kenneth Fong-Hearst endowed



scholarships to the CSU system and 40 student scholarships to Peking University. In 2003, he was involved with establishing the Fong Optometry and Medical library at UC Berkeley, and more recently an endowed professorship at Stanford University and a technology translation endowed fund at San Francisco State University.

Ken obtained his PhD from Indiana University and his post-doctoral studies at UCLA & NIH.

About CABS K. Fong Award in Life Sciences

The **CABS K. Fong Award** in Life Sciences is an esteemed annual recognition presented to individuals who have made exceptional contributions to the fields of life sciences and the biopharmaceutical industry including outstanding scientific findings, recognized efforts in promoting life science education and initiatives in improving life science community, and those who bring therapeutic breakthroughs to the market and improve healthcare and quality of life.

Candidates eligible for this award must be nominated by an active member of CABS. Selection criteria are based on candidate's accomplishments in life sciences and contribution to the life science

community, including one or all of the following:

- Proven achievements in therapeutic breakthroughs (including discovery, process, or clinical development), diagnostics or research reagent/equipment markets.
- Significant contribution to the promotion of academic and industrial R&D in biomedical sciences and applications.
- Significant contribution to the CABS community and promotion of international collaborations in life sciences.

Past Recipients of CABS K. Fong Awards

2025

Dr. Liqun Luo, Ann and Bill Swindells Professor of Biology at Stanford University, and Howard Hughes Medical Institute Investigator for his outstanding achievements, which have advanced the frontiers of brain science and contributed to improved human health.

2024

Dr. Zach Sweeney, Venture Partner at Versant Ventures, CEO and co-founder of Interline Therapeutics, CSO at Denali Therapeutics for his exceptional contributions and transformative impact on the pharmaceutical and biotechnology fields.

2023

Dr. Corey Goodman, Managing Partner at venBio, for his groundbreaking discoveries in neural development and axon guidance, as well as his visionary leadership in translating science into successful biopharmaceutical ventures that have significantly advanced human health.

2022

Dr. Scott Liu, Founder and CEO of HanchorBio, for his outstanding and pioneering contribution to the development of multiple biologic products from research to launch.

2021

Dr. John O. Link, Vice President of Gilead Sciences for his work on the drug discovery of Hepatitis C inhibitors and the HIV Capsid Inhibitor; and **Dr. Xian-Ping Lu**, Chairman, CEO of Shenzhen Chipscreen Biosciences Co. LTD, for their extraordinary achievements in research, innovation and entrepreneurship.

2019

John V. Oyler, Chairman, Co-Found and CEO of BeiGene, for his entrepreneurship and business leadership to establish BeiGene as a world-class biopharmaceutical company.

2018

Dr. Yuling Luo, Founder, CEO and Chairman of Alamar Biosciences (formerly the founder & CEO of Advanced Cell Diagnostics, ACD), and **Dr. Guoliang Yu**, Executive Chairman of Crown Bioscience, for their successful serial entrepreneurship in the life science business.

2017

Dr. Yinxiang Wang, Co-founder and CSO of Beta Pharma, for his role in leading development and commercialization of Conmana®, the first small molecule oncology drug specifically targeting cancer cells that was completely developed in China; and **Dr. Edgar Engleman**, for his pioneering research that was the basis of the Sipuleucel-T (Provenge) prostate cancer vaccine, the first active immunotherapy for cancer to be approved by the FDA.

2016

Dr. Gerald Chan, Co-founder of Morningside, for his extraordinary vision and leadership in cultivating a generation of successful entrepreneurs and life sciences companies.

2015

Dr. Irving Weissman, Professor of Stanford University, for his pioneering work in stem cell research.

2014

Dr. Ge Li, Founder and CEO of Wuxi Apptec, for pioneering and shaping the CRO business model in China; and **Dr. Hing L. Sham**, formerly of Abbott for his leading role in the discovery of life-saving HIV protease inhibitors, ritonavir and lopinavir.

2013

Dr. Peter Hirth of Plexxikon & Sugen for his pivotal role in advancing 4 successful drugs to the market; and **Dr. Jean Cui**, formerly of Pfizer for her role as the lead designer and investigator of crizotinib, a successful kinase inhibiting drug used in personalized medicine.



Chinese American Bio/Pharmaceutical Society (CABS)

The Chinese American Bio/Pharmaceutical Society (CABS) proudly announces **Dr. Randy Schekman**, Professor in the Department of Molecular and Cell Biology, University of California, Berkeley, and an Investigator of the Howard Hughes Medical Institute, Nobel Prize Laureate and **Dr. Joseph C. Wu**, Director of Stanford Cardiovascular Institute and Simon H. Stertz, MD, Professor of Medicine and Radiology at Stanford University as the recipients of the prestigious 2026 CABS K. Fong Award in Life Sciences. Marking the 13th anniversary of this esteemed accolade, the award honors Dr. Schekman and Dr. Wu for their exceptional contributions to research, education, and translational innovation. The award will be presented at the 2026 BioPacific Conference on September 19, 2026, at the South San Francisco Conference Center.

DR. RANDY SCHEKMAN &
DR. JOSEPH C. WU

Dr. Randy Schekman is a Professor in the Department of Molecular and Cell Biology, University of California, Berkeley, and an Investigator of the Howard Hughes Medical Institute. He studied the enzymology of DNA replication as a graduate student with Arthur Kornberg at Stanford University. His current interest in cellular membranes developed during a postdoctoral period with S. J. Singer at the University of California, San Diego. Among his awards are the Gairdner International Award, the Albert Lasker Award in Basic Medical Research and the Nobel Prize in Physiology or Medicine, which he shared with James Rothman and Thomas Südhof. He is a member of the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences, the American Philosophical Society, a Foreign Associate of the Accademia Nazionale dei Lincei, a Foreign Associate of the Royal Society of London and an Honorary Academician of the Academia Sinica. In 1999, he was elected President of the American Society for Cell Biology. From 2002-2017, he served as Editor-in-Chief of the Annual Reviews of Cell and Developmental Biology. From 2006 - 2011 he served as Editor-in-Chief of the Proceedings of the NAS. In 2011, he founded and until 2019 served as the Editor-in-Chief of the Open Access journal, eLife, sponsored by the HHMI, Wellcome Trust and the Max Planck Society. Beginning in 2019, Schekman became the scientific director of Aligning Science Across Parkinson's, an effort supported by the Sergey Brin Family Foundation to identify and support basic research on the mechanisms of Parkinson's Disease initiation and progression (parkinsonsroadmap.org).



Schekman's laboratory investigates the mechanism of membrane protein traffic in the secretory pathway in eukaryotic cells. Currently the lab investigates the mechanism of biogenesis and function of extracellular vesicles and the unconventional secretion of alpha-synuclein as a potential means of the spread of brain pathology in Parkinson's Disease.

Joseph C. Wu, MD, PhD, is Director of the Stanford Cardiovascular Institute and the Simon H. Stertz, MD, Professor of Medicine and Radiology at Stanford University. A physician-scientist and cardiologist, Dr. Wu leads a diverse research program spanning induced pluripotent stem cells, organoids, genomics, artificial intelligence, precision medicine, and drug discovery.



His laboratory has advanced the concepts of "new approach methodologies" (NAMs) and "clinical trial in-a-dish" (CTiD). He has published >600 manuscripts with an H-index of 156. Dr. Wu has received numerous prestigious awards, including National Institutes of Health (NIH) Director's New Innovator Award, NIH Roadmap Transformative Award, Presidential Early Career Award for Scientists and Engineers (PECASE) given out by President Obama at the White House, American Heart Association (AHA) Distinguished Scientist Award, American College of Cardiology (ACC) Distinguished Scientist Award, and the ASCI Stanley J. Korsmeyer Award. He served as past President of the AHA (2023-2024) and is current President of the Association of University Cardiologists (2026-2027).

Dr. Wu is a member of the National Academy of Inventors (NAI), National Academy of Medicine (NAM), and American Academy of Arts and Sciences (AAA&S). He is a co-founder of Greenstone Biosciences (www.greenstonebio.com), a startup that uses clinical genomics, human organoids, and AI for drug development.

CABS is honored to recognize Dr. Schekman and Dr. Wu's outstanding achievements, which have advanced the frontiers of science and contributed to improved human health. Their commitment to rigorous research, education, and innovation exemplifies the values of the K. Fong Award in Life Sciences.

For media inquiries and press registration for the award ceremony, please contact: info@cabsweb.org.

KEYNOTE SPEAKERS



FLAVIUS MARTIN

Flavius Martin (MD, PhD) is the Executive Vice President of Research at Gilead Sciences, overseeing internal discovery research and identification of external opportunities across all therapeutic areas. Flavius joined Gilead in 2021, after 20 years in the biopharmaceutical industry at Amgen and Genentech. Flavius received his MD degree from the University of Medicine and Pharmacy Timisoara, Romania and completed postdoctoral studies at the University of Alabama at Birmingham in the Division of Developmental and Clinical Immunology.

ELIMINATING PATHOGENIC MECHANISMS ACROSS VIROLOGY, ONCOLOGY, AND INFLAMMATION

ABSTRACT: Advances in drug discovery are increasingly driven by a deeper understanding of shared biological mechanisms that underlie diverse disease areas. This presentation highlights a strategy centered on eliminating core pathogenic drivers—an approach initially advanced in antiviral research and now being extended across oncology and inflammatory diseases. By bridging traditionally siloed fields, this approach enables the identification of convergent pathways, accelerates innovation, and creates new opportunities for therapeutic impact. Case examples spanning virology and emerging applications in cancer and immune-mediated diseases will illustrate how integrating scientific frameworks across domains can unlock broader and more durable breakthroughs.

Jan Smith (PhD) serves as the Chief Scientific Officer at Revolution Medicines, bringing extensive expertise in molecular pharmacology and a deep commitment to advancing small molecule drug discovery and development. With over two decades of experience in drug discovery R&D within the biopharmaceutical industry, Jan has played a pivotal role in identifying numerous clinical candidates spanning diverse disease areas. Before joining Revolution Medicines, Jan held leadership roles at Theravance Biopharma and Roche Bioscience, further solidifying her leadership and strategic contributions in the field. Jan’s significant contributions extend to academia, with her co-authorship on over 45 peer-reviewed publications and her role as a named inventor on several issued patents and applications. Her dedication to advancing scientific knowledge and improving therapeutic outcomes underscores her impactful career in the biopharmaceutical sector. Jan graduated from the University of Bath, U.K., earning a Ph.D. from the University of Cambridge, U.K., and conducted her postdoctoral research at the University of California, Irvine, and the Sandoz Institute for Medical Research, London, U.K.



JAN SMITH

TARGETING THE ONCOGENIC STATE OF RAS WITH TRICOMPLEX INHIBITORS

ABSTRACT: RAS oncogenic driver mutations are among the most frequent genomic aberrations in human cancers, prevalent in pancreas (~90%), colon (~50%), and lung (~30%) tumors. Small molecule inhibitors that selectively target the inactive, GDP-bound (OFF) state of KRAS G12C mutant proteins have demonstrated clinical efficacy as monotherapy in NSCLC and in combinations with anti-EGFR agents in CRC. However, there are no currently approved RAS-targeted therapy options for patients with non-G12C RAS mutant cancer. We have designed a series of orally bioavailable tri-complex inhibitors that selectively target the GTP-bound, active state of RAS (RAS(ON)), potentially mitigating some of the resistance mechanisms observed with inhibitors that preferentially bind to the OFF state. These include daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor that noncovalently inhibits the active, GTP-bound state of mutant and wild-type variants of all canonical RAS isoforms (KRAS, NRAS, and HRAS), and the mutantselective inhibitors zoldonrasib (RMC-9805) that covalently engages RAS(ON) G12D, elironrasib (RMC-6291) that covalently engages RAS(ON) G12C, and RMC-5127 that noncovalently engages RAS(ON) G12V. I will describe the mechanism of action of these investigational agents and their activity in a variety of RAS-driven preclinical models that supports their ongoing clinical evaluation in RAS-driven cancers. Our emerging understanding of acquired resistance to RAS(ON) inhibitor monotherapy, in both preclinical and clinical settings, is now informing combination regimens for clinical evaluation, including RAS(ON) inhibitor doublets, as a strategy to mitigate resistance mechanisms. We have also identified a new class of oral, mutant-targeted catalytic RAS(ON) inhibitors, exemplified by RM-055, that mimic the activity of natural GAPs stimulating the GTPase activity of oncogenic RAS mutants. These inhibitors can overcome acquired resistance to RAS(ON) inhibition in preclinical models with elevated oncogenic RAS signaling, including mutant RAS amplification.



KETING CHU

Keting Chu (MD, PhD) is an experienced biotech executive, entrepreneur and life science venture investor with a broad range of experiences in therapeutic development in both large and small biotechnology companies and venture investments.

Prior to founding Bluejay, Keting was a Partner and a Venture partner at LYFE Capital. Working with the team in Lyfe capital, Keting helped to close \$550M Lyfe Capital Fund III and invested in Ansun Biopharm, Pliant Therapeutics and Tempest Therapeutics. Pliant and Tempest went IPO in NASDAQ successfully in 2020 and 2021. Keting was a venture partner in Apple Tree Partners briefly. Before joining Apple Tree Partners, Keting spent five years as VP, Research TAP at The Leukemia and Lymphoma Society (LLS). There she was responsible for venture philanthropy, also known as the Therapy Acceleration program. At LLS, Keting led the investment into Celator, Stemline, Constellation, Affimed, ArgenX, Kite Pharma, Kiadis, OncoPep, Valor and a number of projects in academic institutions with the focus on proof-of-concept (POC) studies in patients. Three of the nine companies received “Breakthrough” designation by the FDA in 2016 after positive proof-of-concept studies. Celator was acquired by Jazz Pharma for \$1.5B, Kite by Gilead for \$12B and Stemline by Menarini for \$677M. Three NDAs, by Celator, Kite and Stemline, were approved by the US FDA successfully. Prior to LLS, Keting was the CEO of Mission Therapeutics and the Co-Founder, President and CEO of DigitAB, Inc. and BioCubed Corporation.

For her first startup company, Five Prime Therapeutics, Keting was Vice President of Biology and Head of R&D where she built the R&D strategy and team, established the technology platform and generated a product pipeline. Prior to Five Prime, Keting was the Head of Immunotherapy and Antibody Therapeutics Division at Chiron Corporation, where she engaged in preclinical and clinical developments of protein, DNA-based, and small molecule therapeutics for cancer and inflammatory diseases. Three cancer therap

THE BLUEJAY STORY

ABSTRACT: Bluejay Therapeutics Inc, a Delaware corporation, was located in the Bay Area with a mission to develop innovative therapeutics and treatments for viral and liver diseases with urgent unmet medical needs. It started being operational in June 2021 with licensed assets from Novartis. And was acquired by merging in January 2026 for \$820M. The lead asset, Brelovitug, that Bluejay licensed was at preclinical development candidate stage at Novartis. It’s a highly potent neutralizing human monoclonal antibody against HBsAg, the surface antigen of the human hepatitis B virus (HBV). In March 2025, Bluejay dosed the first patient in the global phase 3 registrational trial. Data from the phase 2 trial showed Brelovitug is efficacious and safe as antiviral in patients suffering from chronic viral hepatitis D (CHD) with 100% response rate. CHD is the most severe form of viral hepatitis, the 10 year survival rate is less than 50% and there is no FDA approved treatment available. It took Bluejay less than four years to develop it from preclinical to phase 3 registrational trial. The Bluejay team worked hard and smartly with urgency.

Yuling Luo (PhD) is CEO and Chair of Alamar Biosciences and a serial life sciences entrepreneur. Prior to co-founding Alamar, Yuling co-founded Advanced Cell Diagnostics (ACD) where he served as president and chief executive officer until its acquisition by Bio-Techne. At ACD, he invented RNAscope, a breakthrough molecular detection technology that has pioneered spatial biology and become the gold standard in RNA tissue imaging. Prior to ACD, Yuling co-founded Panomics, a life science company that was acquired by Affymetrix, where he served in various roles including Chief Scientific Officer. He co-founded and served as board chair of Avida Biomed (acquired by Agilent) and co-founded and serves as a board member for Attovia Therapeutics. Yuling is a venture partner of Illumina Ventures, has published numerous research papers in top peer-reviewed journals and his inventions are the subject of over 30 issued patents. He received a B.S. in Chemistry from the University of Science & Technology of China and earned a Ph.D. in Biochemistry from Case Western Reserve University..




YULING LUO

POWERING PRECISION PROTEOMICS TO ENABLE THE EARLIEST DETECTION OF DISEASE.

ABSTRACT: Proteomics has the potential to transform our understanding of health and disease the way genomics did a generation ago, enabling better treatments and longer, healthier lives. Despite its immense promise, the field has been held back by the limitations of existing proteomics technologies. Alamar Biosciences has developed a Precision Proteomics platform, including NULISA chemistry and the ARGO HT instrument, that uniquely combines five critical elements of performance required for precision medicine and early detection of disease. For the first time, the field has a technology that promises to unleash the full power of proteomics.

K. FONG AWARDEE SPEAKERS

Randy Schekman (PhD) is a Professor in the Department of Molecular and Cell Biology, University of California, Berkeley, and an Investigator of the Howard Hughes Medical Institute. He studied the enzymology of DNA replication as a graduate student with Arthur Kornberg at Stanford University. His current interest in cellular membranes developed during a postdoctoral period with S. J. Singer at the University of California, San Diego. Among his awards are the Gairdner International Award, the Albert Lasker Award in Basic Medical Research and the Nobel Prize in Physiology or Medicine, which he shared with James Rothman and Thomas Südhof. He is a member of the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences, the American Philosophical Society, a Foreign Associate of the Accademia Nazionale dei Lincei, a Foreign Associate of the Royal Society of London and an Honorary Academician of the Academia Sinica. In 1999, he was elected President of the American Society for Cell Biology. From 2002-2017, he served as Editor-in-Chief of the Annual Reviews of Cell and Developmental Biology. From 2006 - 2011 he served as Editor-in-Chief of the Proceedings of the NAS. In 2011, he founded and until 2019 served as the Editor-in-Chief of the Open Access journal, eLife, sponsored by the HHMI, Wellcome Trust and the Max Planck Society. Beginning in 2019, Schekman became the scientific director of Aligning Science Across Parkinson's, an effort supported by the Sergey Brin Family Foundation to identify and support basic research on the mechanisms of Parkinson's Disease initiation and progression (parkinsonsroadmap.org). Schekman's laboratory investigates the mechanism of membrane protein traffic in the secretory pathway in eukaryotic cells. Currently the lab investigates the mechanism of biogenesis and function of extracellular vesicles and the unconventional secretion of alpha-synuclein as a potential means of the spread of brain pathology in Parkinson's Disease.



RANDY SCHEKMAN

TACKLING PARKINSON'S DISEASE WITH BASIC SCIENCE

ABSTRACT: Biomedical science has delivered tremendous strides in the treatment of heart disease and cancer. In contrast, progress on the incurable neurodegenerative diseases, such as Alzheimer's and Parkinson's Disease (PD), has lagged. We face a burgeoning elderly population at risk and a health care system strained to the limit. There are a few clues as to the molecular processes that may mediate the progressive death of dopaminergic neurons which appears to be the root cause of Parkinson's Disease, but much work is required to develop an understanding that will lead to effective therapies. In an effort to break through the cloud of uncertainty as to the origin and means of progression of PD, a new effort focused on basic science has been launched under the title: Aligning Science Across Parkinson's Disease (parkinsonsroadmap.org). Our program, supported with private philanthropy by the Sergey Brin and Michael J. Fox Foundations, focuses on basic disease processes including the genes and proteins implicated in familial forms of PD, the neuroinflammatory processes that may instigate or exacerbate disease progression, the neural circuitry that feeds into and from dopaminergic neurons and an understanding of the processes that may predict or initiate disease in the long prodromal phase that precedes the development of movement disorder symptoms. We have assembled teams of investigators who have developed meaningful collaborations on these key issues, and from these groups we have built an international collaborative research network (CRN) who share a vision for open communication of ideas and results.



JOSEPH C. WU

Joseph C. Wu (MD, PhD) is Director of the Stanford Cardiovascular Institute and the SimonH. Stertz, MD, Professor of Medicine and Radiology at Stanford University. A physician-scientist and cardiologist, Dr. Wu leads a diverse research program spanning induced pluripotent stem cells, organoids, genomics, artificial intelligence, precision medicine, and drug discovery. His laboratory has advanced the concepts of "new approach methodologies" (NAMs) and "clinical trial in-a-dish" (CTiD). He has published >600 manuscripts with an H-index of 156. Dr. Wu has received numerous prestigious awards, including National Institutes of Health (NIH) Director's New Innovator Award, NIH Roadmap Transformative Award, Presidential Early Career Award for Scientists and Engineers (PECASE) given out by President Obama at the White House, American Heart Association (AHA) Distinguished Scientist Award, American College of Cardiology (ACC) Distinguished Scientist Award, and the ASCI Stanley J. Korsmeyer Award. He served as past President of the AHA (2023-2024) and is current President of the Association of University Cardiologists (2026–2027). Dr. Wu is a member of the National Academy of Inventors (NAI), National Academy of Medicine (NAM), and American Academy of Arts and Sciences (AAA&S). He is a co-founder of Greenstone Biosciences (www.greenstonebio.com), a startup that uses clinical genomics, human organoids, and AI for drug development.

NEW APPROACH METHODOLOGIES: FROM GENOMIC MEDICINE TO CLINICAL TRIAL IN DISH

ABSTRACT: Drug discovery and development continue to face significant challenges, with over 90% of candidate drugs failing in clinical trials. These efficacy failures are primarily due to inherent species-specific differences, fundamental biological variances between model organisms and humans, and the limitations of existing models to accurately reflect the complexity of human disease and treatment responses. In this discussion, I will explore how the NIH and FDA are advocating for new approach methodologies (NAMs) to reduce or replace animal testing. I will highlight recent advancements in technologies such as stem cells, organoids, and microphysiological systems (MPS), along with the roles of clinical genomics and AI/ML. Additionally, I will examine how these platforms can collaboratively enhance our understanding of rare orphan diseases, facilitate drug discovery, support precision medicine, and enable clinical trials in-a-dish (CTiD).

PANEL ONE: Design for Success – Startup strategy, partnership, and inflection points

MODERATOR - Lu Lu

Lu Lu is an Associate Director of External Partnering at Eli Lilly ExploR&D, where she focuses on identifying and advancing strategic partnerships to accelerate drug innovation. Prior to Lilly, she served as Senior Director of Business Development at MicuRx Pharmaceuticals, leading global licensing and partnership initiatives. Earlier in her career, she held business development and alliance management roles at WuXi AppTec and RheoSense. With experience spanning biotechnology, pharmaceuticals, and life science services, Lu has worked across licensing, alliance management, portfolio strategy, and cross-functional drug development. She is also an active executive committee member with CABS, where she organizes and moderates events connecting leaders from academia, industry, capital to foster innovation and career development in the life sciences.



LULU



WENWU ZHAI

Wenwu Zhai, (MD, PhD) is the Chief Scientific Officer and R&D General Manager of HanchorBio Inc., where he leads multifunctional teams and be responsible for company's overall research strategy, portfolio design, multi-site R&D operations, CMC activities, intellectual property, and project execution from early discovery to IND. He has more than 25 years of experiences in therapeutic antibody and protein drug discovery and development across oncology and immuno-oncology, autoimmune and inflammatory diseases, infectious diseases, neurological disorders, and metabolic diseases. Wenwu is a recognized leader in antibody discovery and engineering with experience spanning target identification, lead selection, characterization, humanization, affinity maturation, Fc engineering, bispecific antibody design, developability assessment, CMC, IND preparation, and early-to-late clinical development. He has participated in more than 30 antibody or protein drug programs at different stages of clinical development and has contributed to more than 100 published or granted antibody patents. His work has included successful FDA IND filings and Phase I and Phase 2 studies, as well as support for business development, licensing, and corporate financing milestones. Before joining HanchorBio, Wenwu held various scientific and leadership positions at Staidson Biopharma USA, NGM Biopharmaceuticals, Genentech, Pfizer, and world-renowned research institutions such as UCSF, ICL, and the University of Cambridge. Wenwu received his Ph.D. in Molecular Biology from the University of Manchester, completed his post-doctoral training from MRC Center, University of Cambridge, and got his M.D. in General Medicine from Xi'an Jiaotong University.

Jaione Maiz (MBA, PhD) is a Senior Director of External Partnering at Eli Lilly's ExploR&D division, part of the Catalyze360 initiative, where she identifies and structures early-stage external collaborations to advance cutting-edge science with the potential to transform patient outcomes. Before joining Lilly, Jaione built a career at the intersection of venture capital and business development, partnering with entrepreneurs and organizations from company formation through Series B, across therapeutics and broader life science technologies, both as an investor and as a hands-on BD advisor to early-stage startups. Jaione holds a PhD in Neurobiology from UCLA, an MBA from the Quantic School of Business and Technology, and a Bachelor's Degree from Northwestern University, and is a graduate of the Stanford GSB Entrepreneurship program. She is also a Kauffman Fellow.



JAIONE MAIZ



JIMMY ZHANG

Jimmy Zhang (MBA, PhD) has 20+ years of experience and expertise in both large pharma and start-up companies, in strategy, management, business development, and operations, as well as in venture investments and board directorship. Jimmy is an executive mentor of the biotech incubator QB3 and Bakar Labs at University of California Berkeley and UCSF, and advises companies in the US, China and Korea on strategy, business development and other operation matters. Jimmy was founder, Chairman and CEO of gene and cell therapy companies AccuGen Group and Vinta Bio and raised over US\$64M from strategic and venture investors. He was a Venture Partner at Lilly Asia Ventures, a Board Director of Just Biotherapeutics when acquired by Evotec. Jimmy was Vice President of Transactions at Johnson & Johnson, where he led the transactional and partnership management activities and strategy in Asia Pacific region in pharmaceuticals, medical devices & diagnostics and consumer products, as well as fund relationship and partnership, and Managing Director, MSD Early Investments – Greater China at Merck & Co. responsible for business development and venture investments, and a member of Merck Research Lab (China) Senior Leadership Team. He was also a Board Director of BeiGene Co., Ltd. and an Advisor Board member of Cenova Ventures. Jimmy was previously SVP Business Development at Synergenics (an accelerator founded and led by Dr. Bill Rutter, one of the founding fathers and pioneers of the biotech industry), a consultant at McKinsey & Company, a registered patent agent in the Palo Alto office of Morrison & Foerster, and a project manager at Chiron Corporation (now part of Novartis). Jimmy was a founding member and former Chairman of BayHelix Group. He is an adjunct professor teaching business development and master degree mentor at Yeehong Business School, having taught over 1,000 students in both the US and China. He holds an MBA from MIT Sloan School of Management, where he was elected as the treasurer of MIT Graduate Student Council; a PhD in biomedical sciences from University of Texas Southwestern Medical Center at Dallas, where he worked closely with three Nobel Laureates. Jimmy published in Cell, Nature, Neuron, and JBC, and holds multiple patents, authored a Book Chapter "The Emergence and Transformation of China in Biotechnology" in Biotechnology Entrepreneurship 2nd edition published by Elsevier in 2020, and co-authored Harvard

Jonathan Norris (JD) Jonathan Norris joined HSBC's Innovation Banking Division in April 2023. He manages healthcare venture relationships and works with investors and companies on commercial banking and debt products.

In addition, for more than a decade, Jonathan has written comprehensive reports on the venture healthcare ecosystem, covering venture fundraising, investment, valuations and exits. These reports have been widely cited in the ecosystem and he often speaks at major investor and industry conferences. He has more than 20 years of healthcare banking experience. Jonathan earned a B.S. in business administration from the University of California, Riverside, and a J.D. from Santa Clara University.



JONATHAN NORRIS

PANEL TWO: Toward the tantalizing goal of AI-enabled drug discovery and development



ZHONGHUA PEI

MODERATOR - Zhonghua Pei

Zhonghua (PhD) is currently the Senior VP of Drug Discovery at Lyterian Therapeutics. He held various positions with increasing responsibilities at Abbott Laboratories, Genentech, Ideaya Biosciences and Neuron23, Inc. He has rich and extensive drug discovery experience in oncology, inflammatory diseases, metabolic disease (diabetes & obesity) and CNS diseases. He has made significant impact and contributions to the discovery of a large number of clinical development candidates at Abbott, Genentech, Ideaya and Neuron23, either as a team leader or an individual contributor. Two of the candidates discovered by his teams are currently in active phase 2 clinical trials. He has authored or co-authored ~47 peer-reviewed papers, reviews and book chapters and ~ 55 patents. Zhonghua obtained his BS degree from University of Science and Technology in China (USTC), MS degree from Rensselaer Polytech Institute (RPI) and Ph D. in chemistry from MIT.

James Zou (PhD), Associate Professor of Biomedical Data Science and, by courtesy, of CS and EE at Stanford. James lead the Stanford AI for Science Lab, with a particular interest in tackling challenges in human disease and health. His algorithms have received FDA approval, are used by millions of developers, and were selected as The New York Times' Good Tech. He received his Ph.D. from Harvard in 2014 and have held positions at Microsoft Research, as a Gates Scholar at Cambridge, and as a Simons Fellow at UC Berkeley. James joined Stanford in 2016, where he was a two-time Chan-Zuckerberg Investigator, a faculty director at the Stanford Data Science Institute, and a member of the Stanford AI Lab. His research has been recognized with the Overton Prize, a Sloan Fellowship, an NSF CAREER Award, multiple best paper awards, and faculty awards from Google, Amazon, Genentech, and Apple.



JAMES ZOU



CHRIS FOTI

Chris Foti (PhD) is currently a Sr. Director in Analytical Development at Gilead Sciences with over 20 years of experience in the pharmaceutical industry in Analytical CMC. He has worked at Abbott Laboratories and Pfizer during his career and received his PhD in Organic Chemistry from North Carolina State University followed by postdoctoral research at the University of North Carolina at Chapel Hill. He has led teams with multifunctional roles such as particle characterization and spectromicroscopy, structure elucidation, low-level analysis for nitrosamines and PMIs, data sciences, analytical support for formulation development and analytical CMC teams with expertise in stress testing best practices and drug degradation pathways to solve stability issues for small molecules. Dr. Foti has authored and reviewed CMC sections for IND, IMPD, MAA, CTD and NDA submissions and participated in GMP audits, pre-approval readiness and pre-approval inspections.

Karen (Yitong) He is a business development leader driving global growth at Cosychem/CosynBio and strategic partnerships across the biotechnology sector. Specializing in CRO and CRDMO solutions across Europe, the USA, and Asia, Karen brings deep domain expertise to the TIDES and RNA therapy landscape, helping pharma and biotech innovators advance complex nucleic acid and peptide programs. With a proven track record of managing cross-border key accounts, she enables international partners to seamlessly scale novel therapies from early preclinical stages through to full commercial GMP production.



KAREN (YITONG) HE

PANEL THREE: Cracking the Code What Attracts Venture Capital in Biotech



JING-SHAN "JENNIFER" HU

MODERATOR - Jennifer Hu

Jennifer Hu (PhD) began her venture capital career in 2016 as a founding Partner of Qiming Venture Partners USA, where she helped launch and invest from U.S. Healthcare Fund I and later served as a Senior Advisor. During her tenure, she led the Series C1 financing of ARMO BioSciences (IO), which was acquired by Eli Lilly for \$1.6 billion in 2018, and contributed to investments in Cadent Therapeutics (CNS, acquired by Novartis for \$560 million in 2020) and Ventyx Biosciences (IGI, acquired by Eli Lilly for \$1.2 billion in 2026).

Prior to her venture investing career, Dr. Hu held leadership roles across partnering, business development and licensing (BD&L), and R&D at both multinational pharmaceutical companies and U.S biotech firms. Her positions included Vice President and Head of (External) Innovation Center China at Bayer Pharmaceuticals, Director of Licensing and External Research at Merck & Co. (MSD), and Head of Functional Biology at Roche Palo Alto.

Dr. Hu is currently an independent advisor, supporting venture investment, BD&L and fundraising efforts for innovative therapeutics companies. She completed her postdoctoral training at Harvard Medical School, earned her PhD from the University of Texas Graduate School of Biomedical Sciences at MD Anderson Cancer Center, and received her BS in Biochemistry from Peking University.

Chen Yu (PhD) is the founder and Managing Partner at TCGX. Prior to founding TCGX, Dr. Yu spent sixteen years as a Managing Partner at Vivo Capital, a life sciences focused investor with \$4.5 B AUM. Dr. Yu has extensive operating experience with leadership roles at both private and public companies, including stints as the COO of Sagent Pharmaceuticals and CBO of China KangHui, both of which went public and were ultimately acquired. Dr. Yu has served on the board of over a dozen private/public companies, including Artios, Upstream Bio, Structure Therapeutics (NASDAQ:GPCR), Arbor Biotechnologies, Tarsus Pharmaceuticals (NASDAQ: TARS), Sagent Pharmaceuticals (NASDAQ: SGNT, acquired by Nichi-I-Ko), China Kanghui (NYSE:KH, acquired by Medtronic), Rempex (acquired by Medicines Company), Kala (NASDAQ:KALA), Nabriva (NASDAQ: NBRV), Surgical Specialties (acquired by GTCR), Sentre Heart (acquired by Atricure), and NKF Pharma (SHA: 603707). While at Vivo, he also led investments in Zai Labs (NASDAQ: ZLAB), RiverVision (acquired by Horizon), CRISPR Therapeutics (NASDAQ:CRSP), Intellia (NASDAQ: NTLA), Durata (acquired by Actavis), Trauson (acquired by Stryker), and Revolution Medicines (NASDAQ:RVMD).

Dr. Yu also serves on the California Leadership Council for the Nature Conservancy and was previously a member of the Stanford Medical School Alumni Board of Governors. Dr. Yu received his M.D. and M.B.A. from Stanford University and graduated magna cum laude with a B.A. in Biology from Harvard University.



CHEN YU

Partner, Lilly Asia Ventures

Judith J. Li (MBA, JD), is a Partner at Lilly Asia Ventures (LAV), based in Menlo Park and focused on early and growth stage investments across biopharmaceuticals, medical devices, and diagnostics both domestically and cross-border. Judith joined LAV in 2013 and has held board appointments at a variety of LAV's portfolio companies, including Inhibrx (INBX: acquired by Sanofi), Structure (GPCR), TMunity (acquired by Gilead) and Just Biotherapeutics (acquired by Evotec). Her prior experience includes McKinsey's New York office, hospital administration at Partners Healthcare, and co-founding an interventional nephrology medical device venture. In addition to her role at LAV, Judith has held various advisory board and non-profit board positions. Judith holds a B.A. in Neurobiology from Harvard and M.B.A. from Harvard Business School.



JUDITH J. LI



LUPING HUANG

Luping Huang (MD, PhD) is Chief Business Officer at Fosun Health Capital, where she leads licensing, strategic investments, and cross-border partnerships to advance innovative therapies for the portfolio companies. Trained as a physician and scientist, she brings a multidisciplinary perspective that combines clinical insight, scientific expertise, and transaction experience in healthcare.



LISA SILVERMAN

Lisa Silverman (PhD, JD) is a partner at Morrison Foerster and a member of the firm's Venture Intellectual Property Group, where she regularly advises investors, emerging companies, and transaction teams on IP due diligence, patentability and freedom-to-operate assessments, and intellectual property considerations in licensing, financing, and M&A transactions. Her practice focuses on patent portfolio management and strategic patent counseling in the life sciences, pharmaceutical, and chemistry sectors. She co-leads the firm's Pharmaceutical Patent practice and serves on its Life Sciences + Healthcare Leadership Team.

LUNCH BREAK & NOON SESSION

ALTRUIST BIOLOGICS

Rubin Jiang is the Senior Director of Manufacturing Science and Technology (MSAT) and Clinical Manufacturing at Altruist Biologics, an Innovent Biologics' CDMO, where he leads technical strategy and manufacturing support for biologics programs spanning process development, technology transfer, and manufacturing. With more than a decade of experience in bioprocess development and manufacturing, he has played a key role in advancing biologics from early-stage development through clinical and commercial production. Prior to joining Altruist Biologics, Rubin served as Director of Antibody Process Development and MSAT at GenScript ProBio. He also held leadership positions in upstream process development at HJB Bio and spent nearly six years at Merck leading upstream process development, scale-up, technology transfer, and implementation of advanced Process Analytical Technology (PAT) across bioreactor scales ranging from 2 L to 500 L. Rubin earned his Master's Degree in Biotechnology at Northeastern University.



RUBIN JIANG



XIAOMING HONG

ORGAN-ON-A-CHIP: CORE PLATFORM FOR NEXT-GENERATION PRECLINICAL DRUG EVALUATION

Xiaoming Hong is chairman of Tianjin Harbios Biomedical Technology Group, MSc in Biochemical Engineering from the University of Birmingham, UK, vice president of Southern California Medical Technology Association, guest professor of NMPA advanced Institute for Executive Development, expert member of the Working Group for the Drug Inspectors Training Syllabus for NMPA, visiting Professor of Shanghai University, innovation and entrepreneurship mentor for Nankai University, vice chairman of Tianjin Nucleic Acid Industry Alliance, chairman of Tianjin Nucleic Acid Drug Technology Service Center.



MINGFENG BAI

ACCELERATING DRUG DISCOVERY THROUGH PARTNERSHIP WITH CRO

Mingfeng Bai is SVP of Medicilon Inc.

2026 BioPacific Conference

SESSION CHAIRS TEAM



Mengning "Frank" Zhou
PhD, ChFC®, CLU® Financial Planner,
MassMutual Financial Group



Amy Yang
Scientist, Bayer



Le Cai
Scientist, A&P Inphatec



Shicheng Guo
Senior Director,
Arrowhead Pharmaceuticals



Yanan Wang
Sr. Scientist QLSF Biotherapeutics



Liang He, PhD
Scientist, Frontage Laboratories



Wenjia Gu, PhD
Scientist, Sutro Biopharma



Science & Technology Poster Session:

CULTIVATING THE NEXT GENERATION OF BIOTECH/BIOPHARMA SCIENTISTS

The 2026 BioPacific Conference is proud to host its inaugural Science & Technology Poster Session, showcasing the creativity, curiosity, and scientific achievements of emerging talents in the biotechnology community. This special session features research and innovation posters presented by high school students and CABS Summer Interns selected through a competitive abstract review process. Covering topics

-ranging from biotechnology and data science to analytical, clinical, and translational research, these presentations provide young scientists with a unique opportunity to engage with industry professionals, share their work, and develop their scientific communication skills. Through this initiative, CABS aims to inspire, mentor, and support the next generation of innovators who will shape the future of biotechnology.

AUTHOR	AFFILIATION	POSTER TITLE
Andrew Li	Aragon High School, CA, USA	Evaluating Machine Learning Models for Cardiovascular Outcome Prediction: Toward a Clinical Decision Support Tool
Alex Meng	Dublin High School, CA, USA	Beyond Simulation: Evaluating the Educational Strengths and Limitations of Virtual Reality in Surgical Training
Ellie Shen, Yuhan Wang, Alisa Huang, Elliot Lu, Annie Cheng, Grace Dong, Joy Lu, Binbing Dong, Jenny Huang, Bing Yu	Cell Lab Tech, Inc. CA, USA	Time-Resolved Phenotypic and Transcriptomic Responses of Primary Canine Dermal Fibroblasts to Prolonged Hypothermic Stress
Christina Fu	2026 CABS Data Science Summer Intern	OpenRepurpose: An AI-Driven Evidence Integration Framework for Target Validation and Drug Repurposing
Sicheng Chen	2026 CABS Data Science Summer Intern	From Expression Signatures to Druggable Targets: A Citation-Grounded AI Agent for Lung Adenocarcinoma Target Evidence Dossiers
Shucheng Cao	McGill University, Quantitative Life Sciences, Canada	CausalSentinel: An Evidence-Traceable Multi-Database LLM Agent for Drug-Target Triage
Ze Tristan Shi (Zechuan Shi)	UC Irvine, CA, USA	From Prognosis to Treatment Prioritization: A Cancer-Stratified Multi-Omics Framework Separating Prognostic, Actionable, and Predictive Evidence

2025-2026

SELECTED CABS ACTIVITIES

Frontiers in Healthcare, Global Impact in Action

2025 CABS BioPacific Conference | September 13, 2025 | South San Francisco Convention Center



A packed ballroom reflects the scale and energy of the 2025 BioPacific Conference.

800+
ATTENDEES

NEARLY 60
COMPANIES IN THE EXHIBITION HALL

6
FEATURED SCIENTIFIC SPEAKERS

3
HIGH-PROFILE PANEL FORUMS

A Flagship Gathering for Science and Partnership

The annual flagship event of the Chinese American Biopharmaceutical Society (CABS) brought together leaders from academia, biopharma, startups, investment, healthcare, policymaking, and industry associations. Under the theme “FRONTIERS IN HEALTHCARE: Forging Global Impact Through Science, Innovation, and Partnership,” participants exchanged perspectives on scientific advances, industry challenges, and emerging opportunities across the global life sciences ecosystem.

Opening the Day

Sihong Zhou, CABS President-Elect and Chair of the 2025 Conference Organizing Committee, welcomed attendees, thanked the partners who made the gathering possible, and framed BioPacific as both a showcase for scientific progress and a hub for cross-sector collaboration.

State of the Society

CABS President Kay Tong delivered the “State of the Society” address, reviewing progress in academic exchange, industry collaboration, and young-talent development. She reaffirmed CABS’s commitment to openness, innovation, and partnership, and its role connecting the United States, China, and the broader Pacific Rim life-science community.

2025 CABS K. Fong Award in Life Sciences

Liqun Luo, PhD, Ann and Bill Swindells Professor of Biology at Stanford University and a Howard Hughes Medical Institute Investigator, received the award for pioneering contributions to neuroscience and brain-function research. The presentation by Sihong Zhou, Kay Tong, Dr. Kenneth Fong, and others drew sustained applause from the audience.



Sihong Zhou welcomes attendees and opens the 2025 BioPacific Conference.



Kay Tong delivers the “State of the Society” address.



Liqun Luo receives the 2025 CABS K. Fong Award in Life Sciences.

SCIENCE & TRANSLATION 2025 BIOPACIFIC CONFERENCE

01 Science on the Main Stage

Sessions remained filled throughout the day as six distinguished speakers connected foundational discovery with new therapeutic platforms, translational strategy, and AI-enabled medicine.

Liqun Luo, PhD

Stanford University | Howard Hughes Medical Institute

Reviewed milestones in neural-circuit development and functional mapping, underscoring how basic science creates the foundation for medical innovation.



Liqun Luo highlights neural-circuit development and functional mapping.

Howard Y. Chang, MD, PhD

Senior Vice President and Global Head of Research, Amgen

Explored gene regulation and epigenetics in drug development, progress at the intersection of RNA therapeutics and precision medicine, and AI’s potential to accelerate disease research and treatment.



Howard Y. Chang discusses gene regulation and RNA therapeutics.

Margaret Porter Scott, PhD

Vice President and Head of Biochemical and Cellular Pharmacology, Genentech

Highlighted emerging directions in cellular pharmacology and novel drug mechanisms, with an emphasis on systematic strategies that shorten the path from discovery to clinical translation.



Hans-Peter Gerber, PhD

Hans-Peter Gerber, PhD

Chief Scientific Officer, Sutro Biopharma

Presented advances in antibody-drug conjugates and described how innovative platforms can improve drug selectivity and therapeutic efficacy.



Su Guo, PhD

Su Guo, PhD

Professor, University of California, San Francisco | Director, Collaborative Innovation Center

Shared research on neurological-disease modeling and intervention strategies, demonstrating how interdisciplinary teams can accelerate translation from basic research to clinical application.



Lei Xing, PhD

Lei Xing, PhD

Professor and Director, Stanford University

Showed real-world applications of AI in oncology imaging diagnostics and precision radiotherapy planning, and offered a forward view of next-generation imaging-driven therapies.

FROM DISCOVERY TO IMPACT

Across disciplines, speakers emphasized the importance of connecting rigorous science, enabling technology, and effective translation.

IDEAS & PERSPECTIVES
2025 BIOPACIFIC CONFERENCE

02 Three Conversations
Shaping the Industry

Three expert forums brought together perspectives from research, entrepreneurship, investment, and legal practice, giving attendees a layered view of the forces transforming biopharma.

AI Applications in Drug Discovery

Moderator: Zhonghua Pei, PhD, Senior Vice President, Lyterian Therapeutics
Panelists: Lei Xing, PhD (Stanford University); Weian Zhao, PhD (UC Irvine; Founder and CEO, Eureka Biotechnologies); Alex Taylor, PhD (Vice President, Inductive Bio); Ci Chu, PhD (Vice President, Early Discovery, Xaira Therapeutics)

The panel examined generative AI, molecular modeling, and virtual screening across the drug-development process. Alongside recent advances, panelists addressed practical limitations, implementation challenges, and the work still required to translate computational promise into reliable discovery outcomes.

Key themes: Generative AI • molecular modeling • virtual screening • real-world limitations



The AI Applications in Drug Discovery panel examines emerging tools and real-world limitations.

U.S.-Asia Cross-Border Healthcare Investment and Entrepreneurship

Moderator: Cheni Kwok, PhD, CLP, Managing Partner and Founder, Linear Dreams
Panelists: Alexis Ji, PhD, MBA (Founder and Managing Partner, Primer Ventures); Ji Li, PhD (Head of Corporate Development, Propeller Bio); Scott Liu, PhD (Founder, Chairman, and CEO, HanchorBio)

Drawing on firsthand experience, panelists discussed how to identify high-potential innovation opportunities amid global complexity. The conversation also explored emerging financing channels, new partnership models, and practical approaches to building resilient cross-border collaborations.

Key themes: Opportunity assessment • financing channels • partnership models • global complexity



Panelists explore cross-border healthcare investment, financing, and partnership models.

From Startup to Unicorn

Moderator: Janet Xiao, PhD, Partner, Morrison Foerster
Panelists: Carlos E. Solorzano, PhD (Biotech Investor, Ally Bridge Group); Li-Fen Lee, PhD (Founder and CEO, Apeximmune Therapeutics); Chuan Sun, PhD, JD (Partner, Morrison Foerster, Shanghai and Hong Kong); Xiaoling Li, PhD, FAAPS, FAIMBE (Co-Founder and CSO, Triastek, Inc.)

Perspectives from investment, company building, and legal practice framed an end-to-end discussion of biotech growth. Topics ranged from intellectual-property planning and financing to organizational scaling and global expansion, offering practical guidance for emerging ventures.

Key themes: IP strategy • fundraising • company building • global expansion



The From Startup to Unicorn panel shares practical strategies for scaling biotech ventures.

INDUSTRY & COMMUNITY
2025 BIOPACIFIC CONFERENCE

03 Industry Engagement,
Community, and a Memorable
Close

Beyond the main-stage program, sponsor spotlights, exhibition-hall conversations, closing reflections, and the evening banquet extended the day's exchange from ideas to relationships and community impact.

Sponsor Spotlights and Exhibition-Hall Exchange

Sponsor presentations added practical, execution-oriented perspectives to the scientific program. Diamond Sponsor speakers Claudia Qiao Lin, PhD, Chief Scientific Officer of Cosychem Technology, discussed innovations in novel delivery systems, while Hongbo Zhang, PhD, Vice President of Drug Discovery Services at HitChem, presented molecular-glue degrader research integrating generative AI with experimental chemistry. Platinum Sponsor Gongshun Wang, North America Regional Manager at Haier Biomedical, highlighted progress in biomedical equipment and international collaboration. Gold Sponsor speakers Sriram Kumaraswamy, Vice President of Product Management and Marketing at Gator Bio, and Lorraine Lu, Senior Director of Business Development at Pharmaron, shared experience in product innovation and global market expansion.



Exhibitors and attendees connect around new technologies, services, and partnership opportunities.



CABS leaders, speakers, volunteers, and partners mark the successful close of the conference.

Closing the Conference

CABS President Kay Tong and President-Elect Sihong Zhou thanked the speakers, sponsors, volunteers, and participants, and reaffirmed the BioPacific Conference as a bridge for cross-sector collaboration. A group photo captured the successful close of a full and inspiring day.



The evening reception extends conversations, community connections, and collaboration.

Banquet, Connection, and Community

The evening banquet, co-emceed by Wenjia Gu, PhD (BCD Co-chair), and Guanghui Han, PhD (iCC Co-Chair), created a relaxed setting for continued conversation and relationship-building. It also highlighted CABS's public-benefit mission and the importance of giving back to the community.

CONNECTING SCIENCE • ADVANCING INNOVATION • STRENGTHENING PARTNERSHIP

The 2025 BioPacific Conference demonstrated the global potential of life sciences and biopharmaceutical innovation—from frontier discovery and industrial translation to cross-border investment and public-benefit initiatives.

We look forward to seeing everyone again next year.

2025 - 10/25

AI-Powered Advances in Small-Molecule Drug Discovery

On October 25, 2025, the Science & Technology Committee (STC) of the Chinese American Bio/Pharmaceutical Society (CABS) hosted the half-day workshop, “Smarter Molecules, Faster Cures: AI-Powered Advances in Small-Molecule Drug Discovery,” in Burlingame, California. Co-chaired by Dr. Liping Meng (Gilead) and Dr. Alex Yang (Vir Biotechnology), the event brought together more than 90 scientists, entrepreneurs, and AI innovators from academia and the biopharmaceutical industry to explore how artificial intelligence is reshaping small-molecule drug discovery.

The scientific program featured six speakers highlighting complementary approaches across the discovery pipeline and development advancement. Dr. Wenhao Gao (Stanford University) discussed generative modeling for designing novel, synthetically accessible molecules. Dr. Jin Wang (Baylor College of Medicine) presented high-throughput proteomics strategies for discovering molecular glues and covalent drugs. Dr. Yuxing Peng (NVIDIA) demonstrated hybrid AI-physics approaches combining molecular dynamics and machine learning to improve molecular prediction. Dr. Zhe Wu (Exelixis) introduced

machine-integrated drug discovery and emphasized a “predict-first” culture that combines AI/ML with physics-based methods. Dr. Alejandra Trejo-Martin (Gilead Sciences) reviewed toxicological assessment and regulatory considerations for impurities, while Dr. Hongbo Zhang (HitChem) showcased generative AI approaches for developing focused CRBN molecular-glue libraries.

A lively panel discussion addressed critical challenges, including data quality, dataset harmonization, experimental validation, regulatory concerns, and the need for stronger academic–industry collaboration. Participants emphasized that the future lies not in replacing scientists with AI, but in effectively integrating AI, physics, experimental science, and human expertise.

The workshop concluded with networking and enthusiastic exchanges among participants.

This event was proudly sponsored by HitChem, whose generous support helped make this workshop possible.



2026 - 01/14

CABS Investor Forum

Organizer: CABS BCD & Morrison Foerster
Sponsor: WuXi Biologics
Location: Morrison Foerster, San Francisco, CA

On January 14, 2026, the Business and Career Development (BCD) Committee of the Chinese American Biopharmaceutical Society (CABS) and Morrison Foerster hosted the 2026 CABS Investor Forum in San Francisco. The event brought together nearly 300 attendees, including more than 70 investors, for a day of investment insights, cross-border deal discussions, and startup presentations.



Keynote: Healthcare Investment Landscape

Jonathan Norris, Managing Director of HSBC Innovation Banking, provided a data-driven overview of the venture healthcare landscape. He highlighted the shift from the 2021 funding peak toward a more cautious environment characterized by larger \$100M+ mega rounds, capital

efficiency, and later-stage investment. Biopharma remained the leading sector, while platform technologies and AI-enabled drug discovery continued to attract significant interest. Norris also noted strong M&A activity in 2025 and expressed cautious optimism for a stabilizing investment environment in 2026.

PANEL 1: Cross-Border Investment

Moderated by **Janet Xiao**, Partner at Morrison Foerster, the first panel examined opportunities and challenges in China–U.S. biotech investment. Panelists highlighted China’s strengths in **innovation speed, engineering efficiency, and clinical execution**, while emphasizing the importance of strong IP, clinical differentiation, trust, and transparency. The **NewCo model** was discussed as one approach to managing development and geopolitical risks. Despite increasing regulatory and national-security scrutiny, panelists emphasized that cross-border collaboration remains critical to advancing global healthcare innovation.

Startup Roadshows

Eight emerging companies presented innovative technologies across **AI-enabled clinical software, cancer organoids, CAR-T, RNA therapeutics, Alzheimer’s disease, obesity, and fibrosis**. The companies presented a wide range of fundraising opportunities, from seed-stage financing to larger rounds supporting clinical development and manufacturing.

PANEL 2: Building the Next Generation of Global Biotech Leaders

Moderated by **Wentao Zhang**, Co-CEO of Frontage Laboratories, the second panel brought together biotech founders, investors, CRO leaders, AI experts, and academic educators. Discussion focused on what is attracting investment today, the growing role of AI across drug development, and the importance of **patient impact, scientific differentiation, high-quality data, and capital-efficient execution**. Panelists identified longevity, neurodegeneration, RNA therapeutics, cell therapy, and senior health as promising areas while emphasizing that AI should complement—not replace—strong science.

Closing

The forum concluded with remarks from **Sihong Zhou**, CABS President, who thanked the speakers, sponsors, volunteers, and participants. The successful event demonstrated CABS’s continued commitment to connecting **science, investment, entrepreneurship, and global collaboration** to advance the future of biotechnology.





2026 - 01/24

Genetic Medicine Workshop: Expanding Horizons in RNA and DNA Therapeutics

The Science & Technology Committee (STC) of the Chinese American Biopharmaceutical Society (CABS) hosted the Genetic Medicine Workshop, “Expanding Horizons in RNA and DNA Therapeutics: Delivery Technologies and Beyond.” Sponsored by CoSynBio, the event brought together more than 70 scientists and industry leaders from academia and biopharmaceutical companies to explore emerging delivery technologies and enabling platforms for RNA and DNA therapeutics.

The workshop opened with remarks from Dr. Sihong Zhou, President of CABS, followed by an introduction to the scientific program by Dr. Alex Yang, Co-Chair of the STC. Four presentations highlighted advances addressing critical challenges in genetic medicine, including biodistribution, endosomal escape, nuclear entry, and targeted delivery.

Dr. Jingjing Zhou (Cosychem/Cosyngen) discussed AI-enabled lipid nanoparticle (LNP) design and organ-specific nucleic acid delivery. Dr. Lijun Huang (formerly Poseida Therapeutics) presented DNA-LNP platforms for in vivo liver targeting and gene insertion, highlighting strategies to improve nuclear delivery and reduce inflammatory responses. Dr. Kai-Yuan Chen (Scribe Therapeutics) introduced a “lab-in-the-loop” framework integrating next-generation sequencing, multimodal AI, and automated experimentation to accelerate CRISPR therapeutic development. Dr. Ivy Fu (Eurofins) reviewed advances in RNA

therapeutics, including engineered LNPs, antibody-conjugated LNPs, and Antibody–RNA Conjugates for targeted delivery.

The closing panel discussion, moderated by Dr. Alex Yang, explored delivery modality selection, translational and regulatory challenges, long-term safety, ethical considerations, and the expanding role of AI-enabled data integration. Participants emphasized that robust analytics, improved translational models, and innovative delivery technologies will be essential to advancing RNA and DNA therapeutics.

The workshop concluded with an engaging networking lunch and enthusiastic feedback from attendees. CABS sincerely thanks all speakers, organizers, volunteers, and participants, with special appreciation to CoSynBio for its generous sponsorship and support in making this workshop possible.

2026 - 02/21

2026 Chinese New Year Gala

On February 21st, over 350 guests gathered at the Sandpiper Community Center in Redwood City, CA, for the 2026 CABS Lunar New Year Gala, celebrating the Year of the Horse. Hosted by the Social Life Committee of the Chinese American Biopharmaceutical Society (CABS), the 4-hour celebration featured over 12 vibrant performances, including live music, vocal solos, and traditional and modern dance routines by local artists. Attendees enjoyed traditional Spring Festival activities such as riddle-solving games, cultural displays, and a prize raffle with dozens of giveaways, alongside authentic Chinese cuisine served to ticket holders. Guests connected with 3 key sponsoring organizations and networked across the Bay Area life sciences community in a festive setting. We thank our dedicated team of over 30 volunteers, performers, and sponsors—GemPharmatech, GenY Financial Advisors, and Vazyme—for making this event a resounding success.



2026 - 03/19

Navigating Business Transactions and Deal-Making in Biotech

The Chinese-American Bio/Pharmaceutical Society (CABS), in partnership with K&L Gates, hosted “Navigating Business Transactions and Deal-Making in Biotech” at Palo Alto Square. The event brought together legal, business, and biotech leaders to discuss key considerations in biotech transactions, intellectual property (IP), fundraising, and strategic partnerships.

CABS President Sihong Zhou opened the event, followed by K&L Gates Partner David Lu, who highlighted the importance of robust IP strategies, thorough due diligence, and clear ownership records in supporting successful biotech transactions. Linda Zhou, Partner at K&L Gates, then examined evolving deal structures, cross-border transactions, and the legal and commercial considerations surrounding mergers, acquisitions, licensing, and founder transitions.

In a fireside chat, Dr. Keting Chu, Founder and CEO of Bluejay Therapeutics, shared her entrepreneurial journey, emphasizing the importance of persistence, strong leadership, fundraising strategy, and clinical progress in building a successful biotech company.

The program concluded with an industry panel discussing trends in licensing, M&A, cross-border partnerships, and biotech financing. Speakers emphasized that successful transactions require not only strong science but also effective IP strategy, regulatory planning, strategic alignment, and trusted partnerships. The evening ended with an engaging networking session among attendees from the biotech and investment communities.



2026 - 03/28

Business Roles in Life Sciences

The Chinese-American Bio/Pharmaceutical Society (CABS), in partnership with the Stanford Chinese Postdoctoral Association (SCPA), hosted **Business Roles in Life Sciences** at Stanford University in Palo Alto, CA. The event explored career transitions from academia to business roles in the biotech industry.

The program opened with remarks from CABS President Sihong Zhou and SCPA Co-chair Lu Liu, and was hosted by Wenjia Gu, Co-chair of Business Career Development (BCD) at CABS. A panel moderated by Denna Kwang (ABclonal Technology) featured industry professionals who shared their career journeys and practical advice.

Key discussions highlighted that business roles emphasize relationship building, communication, and decision-making under uncertainty rather than purely technical expertise. Panelists encouraged scientists to become effective “translators” who can explain complex technologies in simple terms, build strong professional networks, and embrace continuous learning. While AI is transforming the industry, the panel agreed that human judgment, strategic thinking, and relationship management remain essential.

Attendees were advised to refine their personal pitch, stay informed about industry trends, seek mentors, and leverage internal networking opportunities. The event concluded with interactive roundtable discussions, allowing participants to engage directly with panelists, followed by a sponsored lunch and networking session. CABS also invited attendees to its 2026 BioPacific Conference on September 19, focused on **Accelerating Therapeutics: Innovation, Integration, and Impact**.





2026 - 05/03

CABS SLC Fruit Picking & Hiking

Over 50 outdoor enthusiasts and life sciences professionals gathered in Oakland, CA, for the CABS SLC 2026 Spring Hiking Event. Hosted by the Social Life Committee (SLC) of the Chinese American Biopharmaceutical Society (CABS), the outdoor outing featured a 6.6-mile group trek along the scenic Dunn, Graham, and West Ridge Loop trail in Reinhard Redwood Regional Park. Participants completed the loop in a moving time of approximately 2 hours and 39 minutes, navigating lush redwood groves and picturesque ridge viewpoints while enjoying healthy outdoor activity. The event successfully fostered strong community engagement, networking, and wellness among Bay Area professionals.



2026 - 05/30

Translational AI in Biomedicine: From Discovery to Real-World Impact

The Science & Technology Committee (STC) of the Chinese American Biopharmaceutical Society (CABS) hosted the workshop "Translational AI in Biomedicine: From Discovery to Real-World Impact." The event

brought together leading experts from academia and industry to explore how artificial intelligence is accelerating biomedical discovery, translational research, and drug development.

The workshop opened with welcoming remarks from Liping Meng, President-Elect of CABS, followed by an introduction to the scientific program by Dr. Alex Yang, Co-Chair of the STC.

Four scientific presentations showcased AI applications across biomedical innovation. Dr. James Zou (Stanford University) introduced AI "Virtual Labs" and Paper2Agent, demonstrating how specialized AI agents can collaborate, transform scientific publications into reproducible workflows, and accelerate research. Dr. Xi Fang (Innovo Health Labs) presented the concept of the "AI-augmented founder," highlighting how AI can strengthen commercialization strategy, regulatory intelligence, competitive analysis, and evidence-based decision-making.

Dr. Le Cong (Stanford University), joined by Dr. Yingcheng Wu, discussed AI-guided genome and cell engineering, including EvoSSAP, CRISPR-GPT, Genome-Bench, and LabOS, illustrating how AI can enhance molecular-tool design, scientific reasoning, and closed-loop laboratory research. Dr. Michelle Chen (Form Bio) explored AI applications across drug discovery and development, emphasizing the importance of high-quality data, interpretability, interdisciplinary collaboration, and rigorous scientific validation.

The closing panel discussion, moderated by Dr. Lin Wang, examined opportunities and challenges in translating AI innovation into real-world biomedical impact. Discussions emphasized cross-disciplinary talent, reproducibility, human oversight, strategic AI adoption, and the evolving roles of scientists in increasingly automated research environments.

The workshop concluded with enthusiastic feedback and networking opportunities that fostered new connections and collaborations.

This workshop was made possible through the generous support from Innovo Health Labs and ChemScene.



2026 - 06/06

2026 BayArea Dragon Boat Race

The CABS Dragon Boat Team competed in the Bay Area Dragon Boat Corporate Novice Race at Leo J. Ryan Park in Foster City, California. The annual event brought together 36 teams from the biotech, healthcare, and technology sectors for a day of spirited competition.

Guided by the theme "We thrive on challenges!", the CABS team demonstrated remarkable teamwork, resilience, and continuous improvement. From the morning heats to the afternoon finals, the paddlers steadily increased their speed through stronger synchronization, consistent stroke rates, and powerful finishes.

The team improved from 1:51.616 in the seeding race to 1:49.716 in the semifinals and 1:44.662 in the Division 5 Finals—a nearly 7-second (6.2%) improvement over the course of the day.



CABS sincerely thanks every paddler, volunteer, and leadership team member whose dedication, teamwork, and support made this achievement possible. The event showcased the collaborative spirit of the CABS community, and we look forward to racing together again next year.

2026 - 06/27

CABS 2026 EC&Board Member Summer BBQ: Connecting, Inspiring, & Serving Together

The CABS Executive Committee (EC) & Board Summer BBQ, organized by the Office of Operations and the Social Life Committee, brought together EC and Board of Directors (BOD) members at Central Park in San Mateo, California, for an afternoon of networking, team building, and community engagement.

CABS President Sihong Zhou opened the event by reaffirming the society's mission of fostering collaboration, supporting education, and serving the life science community. During the leadership sharing session, the President, President-Elect, BOD members, and Committee Co-Chairs reflected on their CABS journeys, committee initiatives, and volunteer experiences, inspiring members to contribute with greater confidence and purpose.

The afternoon featured three team-building games—Ball Alley, Speed Guess, and Lucky 7—which encouraged teamwork, communication, and camaraderie through friendly competition.

More than a summer gathering, the event celebrated the volunteerism, leadership, and collaboration that define CABS. By strengthening relationships and sharing experiences, participants reinforced a vibrant volunteer community dedicated to advancing the life sciences. CABS sincerely thanks all volunteers, organizers, EC members, and Board members for making the event a memorable success.

AI & Digital Productivity Series

2026 - 07/11

Cross-Border Biotech/Pharma Transaction Case Studies

CABS hosted the webinar “Cross-Border Biotech/Pharma Transaction Case Studies,” attracting over 300 participants from the U.S. and China. Moderated by Guanghui Han, the event featured presentations by Dr. Cheni Kwok of Linear Dreams and Dr. Janet Xiao of Morrison Foerster, followed by an engaging Q&A.

Dr. Kwok explored cross-border deal structures, including licensing, strategic partnerships, and NewCo models, highlighting partner selection and clear communication. Dr. Xiao discussed key legal and IP considerations, including due diligence, FTO, patent protection, export controls, CFIUS, and data privacy.

The webinar provided valuable insights into cross-border transactions and reinforced CABS’s role in fostering global biotech collaboration and knowledge exchange.

The 2026 CABS AI & Digital Productivity Series is a signature capability-building platform designed to develop AI-native professionals and translate emerging technologies into practical improvements in research, operations, collaboration, and decision-making. Led by the CABS IT & Data Science Committee, the series provides hands-on learning across AI tools, digital workflows, automation, team collaboration, knowledge management, and visual communication. More than a collection of workshops, it transforms individual learning into reusable organizational capability—empowering students, scientists, biopharma professionals, volunteers, and leaders to work smarter, innovate faster, and amplify their impact. By turning AI awareness into repeatable skills and scalable practices, the series strengthens CABS’s culture of continuous learning, modernizes how the organization operates, and advances its evolution into an AI-enabled global biopharmaceutical community.

2026 - 06/15-08/25

The CABS Data Science Summer Internship Program is a signature talent-and-innovation platform advancing the future of AI-enabled biopharma. In 2026, the program brings together 29 interns, 15 administrators and mentors, and three program leaders for an intensive 10-week experience addressing real challenges across drug discovery and development. Through expert mentorship, hands-on AI and data-science projects, workshops, and open-source deliverables, participants transform knowledge into practical impact. By connecting emerging talent with accomplished professionals, the program expands CABS’s global reach, strengthens its next-generation leadership pipeline, and demonstrates the power of community-driven innovation.

Setting Sail for Cross-Border Deals



PROGRAM LEADERS

Shicheng Guo

Sihong Zhou

Liping Meng

ADMINISTRATORS & MENTORS

Doris Zhang

Quinn Leng

Yongli Shan

Shichang Miao

Lena Yuan Li

Ying Yang

Zuolin Cheng

Kay Tong

Yuntao Zhang

Alexander Wu

Shicheng Guo

Zhiqing Wang

Elva Huang

Le Cai

Zhuoqing Fang

ABOUT US

EVENTS

Chinese American Biopharmaceutical Society
北美华人生物医药协会

INTERN TEAM

Jah Chen

Yu-Jung Liang

Anagha Gardane

Chengxi Zhang

Hubert Chen

Zechuan Shi

Yichen Dai

Ying Shi

Reuben Addison

Karen Wang

Xiaoxue Li

Wendi Ma

Sicheng Chen

Beyza Yoruk

Tobias Lin

Yifeng Liang

Jingrui Mu

Ivan Yu

Chang Li

Shawn Phan

Lengxi Huang

Jason Zhou

Chin Hung Lin

Matias Pinto

Shucheng Cao

Aaron Wu

Natalie Huang

Christina Fu

Kening Li

To sponsor this outreach program, please contact us at fundraising@cabsweb.org

42

APELOA CDMO SERVICES

TOP 5

CDMO in China

700+

Customers Globally

20

US FDA inspection

With 3 R&D centers in Boston, Shanghai and Hengdian, and Chemical Synthesis Capacity of 11,710 m³ plus BIO-Production Capacity of 7,380 m³. ApeloA enabling global clients in expediting the delivery of affordable medications.

8 Technology Platforms:

- Flow Chemistry
- Peptide
- Synthetic Biology & Biocatalysis
- High Potency Compound

...



ApeloA LinkedIn



Contact Us

info_cdm@apeloA.com

Learn more →

www.apeloA.com



Every Molecule Has A Path Forward

Altruist Biologics is a reliable CDMO and subsidiary of Innovent Biologics providing integrated biologics development and GMP clinical and commercial manufacturing services. We support biotherapeutic programs at any stage from cell line development to aseptic fill-finish.

Guided by our mission to provide a path forward for every molecule, we are committed to creating value for our clients through tailored solutions and a reliable supply of high-quality medicines for patients.

Integrated, One-Stop CDMO Solutions

mAb, BsAb, MsAb, Fusion Protein, Recombinant Protein, ADC and more



CMC Development



Drug Substance Manufacturing



Drug Product Manufacturing



Labeling & Packaging



Quality Control & Analytics



Regulatory Support

Delivering quality and expertise with more than 150 IND/BLA approvals globally and 2,000+ commercial batches.

DNA to IND
in 9 months

~12g/L
Titers

>80%
High Yield



www.altruistbio.com

MORRISON
FOERSTER

We are proud to support the
CABS 2026
BioPacific Conference

MOFO
LIFE SCIENCES + HEALTHCARE

 **HanchorBio** *TWSE: 7827*


Entering the New Space of Immunotherapy Through Myeloid Immune Enhancement

Clinically validated macrophage enhancer platform enabling next-generation immunotherapy



Clinical validation of the HCB101 macrophage enhancement backbone in solid tumors.

HCB101: First Clinical Validation of the Macrophage Immune Backbone

HCB101: Anti-SIRPα mAb	2L Gastric / GEJ Cancer	1L HER2+ Gastric Cancer	2L MSS Colorectal Cancer
	Ramucirumab + paclitaxel	Dual HER2 mAbs + chemotherapy	SOC combinations
	80% ORR	75% ORR	54.5% ORR
	100% DCR	100% DCR	100% DCR
	*Mid-dose evaluable cohort; follow-up ongoing		
	 Durability >60 weeks		

Platform Expansion Beyond HCB101

HCB301 SIRPα x PD-L1 x TGFβ	HCB303 SIRPα x PD-L1 x TIGIT	HCB206 SIRPα x CD20
Next-generation myeloid+ checkpoint + TME modulation	Multi-axis immune activation	Extending macrophage-directed biology into autoimmune disease

 **HCB101 provides clinical proof-of-concept for macrophage immune modulation as a combination backbone.**

Strategic Partnership Opportunities

 Global Licensing

 Co-development Partnerships

 Regional Collaboration

 Pipeline Expansion

 Partner with HanchorBio to advance a clinically validated macrophage immune modulation platform across oncology and immune-mediated diseases.

 **Partnerships**

Scott_Liu@hanchorbio.com
Archer_Hung@hanchorbio.com



Partnering Opportunities
Clinical Programs | Pipeline | Partnering

CoSunBio
BioScience

COSYCHEM

2026

International exhibition

核酸递送与原料一站式解决方案
One-stop Solutions for Nucleic Acid Delivery & Key Materials

- LNP 递送系统 | LNP Delivery Systems
- Formulation optimization
 - Scale-up support • Quality & analytics

- GalNAc系列 | GalNAc Series
- Ligand/linker options
 - Custom synthesis • Tech transfer ready

- 小分子与化学服务 | Small Molecules & Chemical Services
- Route scouting
 - Impurity control • Flexible timelines



Explore Our Products,
Solutions, and Services!

Discovery & Development

CMC-
Manufacturing

CMC- Quality
Control

Preclinical
Studies

Clinical
Studies

ACROBiosystems is a global biotech leader providing recombinant proteins, kits, antibodies, and services to support drug development from discovery to clinic. Trusted by top pharma, we drive innovation and empower progress in biopharmaceutical research.

Recombinant Proteins

Target Proteins • Fc Receptors • Growth Factors • Extracellular Matrix Proteins • Universal Antibodies • Protein-conjugated Beads

Assays & Kits

Inhibitor Screening • Quantitative Biomarker Kits • Residual Detection Kits • ADC Conjugation • Flow Cytometry Assay Kits • TR-FRET Assay Kits

Solutions

ex vivo Cell Manufacturing Solutions • Ready-to-use Organoids for Disease Modeling • One-stop Cell Line Solutions

BsAb Development Solutions • In vivo CAR-T Solution

Custom Services

Custom GMP-grade Protein Service • Cell Line Customization Service • ELISA Service • Recombinant Antibody Development Service

+1 800-810-0816 (Toll Free)

order@acrobiosystems.com

www.acrobiosystems.com

HARBIOS 海河生物

BORDERLESS BIOMEDICAL SOLUTIONS

Tianjin Harbios Biomedical Technology Group Co., Ltd. (hereinafter referred to as Harbios Group) was founded in 2005. It is a platform company specializing in providing full-lifecycle product services for medical device, pharmaceutical research and manufacturing enterprises. Harbios Group has innovatively launched organoid and organ-on-a-chip platforms for pharmaceutical evaluation. These platforms enable high-throughput screening and safety assessment of diverse pharmaceuticals, delivering novel solutions for disease mechanism research, drug discovery and preclinical evaluation, and helping enterprises substantially boost the efficiency and success rate of new drug research and development. We deliver efficient, precise and accessible services to pharmaceutical companies and research institutions worldwide, expediting the commercialization of global pharmaceutical innovations.

Medical Device Services

- Clinical Evaluation
- Regulatory Consulting
- Global Registration & Certification
- Quality Management System Establishment and Audit

Organoid and Organ-on-a-Chip Services

- Drug Discovery and Screening
- Drug Efficacy and Safety Evaluation
- Safety & Efficacy Testing for Innovative Research Areas
- Customized Model Development & Technical Collaboration
- Disease Mechanism Research & Translational Medicine Support

HARBIOS BIOMEDICAL TECHNOLOGY GROUP

sales@harbios.com www.harbios.com
Heartcare 470 Wald Irvine,CA 92618 USA

47

48



See Binding. Unlock Affinity. Accelerate Discovery.

- Measure picomolar to millimolar affinities — no labels, no guesswork
- Analyze small molecules, biologics, and complex antibody formats
- Generate large high-quality kinetic and binning datasets in hours
- Streamline selection, ranking and developability workflows
- Minimize assay development and maximize throughput

Next-Gen Biolayer Interferometry (BLI) for de-risking your decision making and accelerating your pipeline.



Visit gatorbio.com for more information on BLI and to request a demo or quote



GATORBIO.COM



Native-Like Antigens for Antibody Discovery

Off-the-Shelf Proteins & Membrane Proteins to Accelerate Your Research




Off-the-Shelf Antigens



Native-Like Membrane Presentation



Fast Delivery & Consistent Quality



VLP Platform

Transmembrane Proteins Since 2018

- First Target: Claudin 18.2
- ~100 Targets Available
- GPCRs
- Claudins
- Ion Channels

Nanodisc Platform

Reconstituted Membrane Proteins

- Antibody Discovery
- Binding Studies
- Functional Assays
- T Cell Engager Research



Why Choose KACTUS



YUROGEN
A subsidiary of ABclonal



Antibody Engineering



Antibody Discovery



Bioanalytical Services



Recombinant Expression



PK and ADA Assay Reagent Development

- Proprietary STM Platform
- Great Experience in Anti-ID Antibody Discovery
- One Immunization for pAb and mAb Discovery
- Fast Turnaround Time
- Great Diversity
- Professional Project Design



Custom Antibody Conjugation Services

The World's First CD19 Antibody

PRODUCTS • Protein

SPR Service

- High Throughput, 8-Channel System
- Fast Turnaround
- Crude Sample Compatibility



From Idea to IND, Accelerating New Drug Development



Drug Discovery

Chemistry
Biology
Early DMPK



CMC

API / DP
CMC Research
Analysis & Testing Center



Preclinical Research

PD / PK
Drug Safety Evaluation
Bioanalysis



IND Filing

FDA / NMPA
EMA / TGA
MFDS / PMDA

Nucleic Acid Drugs R&D Service Platform

PROTAC R&D Service Platform

XDC R&D Service Platform

AOC R&D Service Platform

NAMs Drug Service Platform

Ophthalmology Platform

CGT R&D Service Platform

GLP-1 New Drug R&D Service

Antibody R&D Service Platform

Peptide Drug R&D Service Platform

Large Animal Pharmacodynamic Service

22⁺

22+ Years of Excellence

650⁺

IND Approved by FDA, NMPA, EMA, TGA, MFDS, PMDA

2000⁺

Active Clients Worldwide

2500⁺

Scientists & Research Staff

990,000⁺

Square Feet of Lab Space

18⁺

Innovative Drugs License-out



Email: gillian.sun@medicilon.com



Turnkey Cleanroom Solutions



Concept Design



Basic Design



Detailed Design



Material and Equipment Supply



After-sales



H.O.



Commissioning & Validation



Construction Management

Established in 1978

Over 210 million square meters of products delivered

210M⁺

Over 16,000 cleanroom system projects delivered worldwide

16,000⁺

Products exported to 70+ countries and regions

70⁺



CONTACT US



Southern Model Organisms


Products and Services



Research-Ready Animal Models



CRO Services



Custom Animal Models



Breeding Services



Let's Connect



www.modelorg.bio



info@modelorg.bio



(346) 859-7340



Sugar Land, TX 77478, USA



49


50



Innovative Drugs
Ask SanyouBio

**AI-STAL • SAI-DA DUAL ENGINE**
POWERING INNOVATION AT THE SOURCE • ACCELERATING GLOBAL DRUG R&D

One-stop solution for real-time discovery of innovative drug R&D



AI-STAL (AI Super Protein Antibody Library)
Up to 100-fold increase in high-quality lead molecules. Screening success rate approaching 100%
Several-fold improvement in speed

One-stop solution for R&D challenges during innovative drug development



SAI-DA (Sanyou AI Drug Accelerator)
Integrates dozens of AI-based algorithms with full process with lab coverage
for preclinical R&D

**Sanyou Biopharmaceuticals Co., Ltd.**
Vision: To become a front-runner in global innovative drug R&D Mission: To make it easy to develop new drugs worldwide
www.clicklinka.com +86 21 3168 1627 service@sanyoubio.com

Contact Us
pharmaron.com
bd@pharmaron.com

PHARMARON is a premier service provider for the life sciences industry with a well-established team of over 25,000 employees working in 28 different sites in China, Singapore, United States and United Kingdom.

MISSION: To support our partners' success in discovery, development and commercialization of innovative medicines

Laboratory
Services

Chemistry,
Manufacturing
and Control

Clinical
Development

Biologics
& CGT

**NONA**
BIOSCIENCES



**TRANSFORMING ANTIBODY DISCOVERY
INTO THERAPEUTIC INNOVATION**

Fully human antibody discovery through
advanced modalities, built for greater
confidence and precision

380+

Programs
Supported

20+

IND/Clinical
-Stage
Programs
Enabled

140+

Global
Partners

**ChemShuttle**
Synthesizing Life

**Premier Chemistry CRO
and Catalogs**



Chemshuttle is dedicated to providing discovery chemistry services and products for new drug research and development and other supporting services to global pharmaceutical and biotechnology companies and institutions.

Services

- * FTE (Full-Time Equivalent)
- * Custom synthesis:
mg to kg,
1-10+ steps,
intermediates/libraries/tool compounds
- * Process chemistry

Products

- * Building blocks (focusing on heterocycles)
- * Bioactive compounds:
reference compounds,
natural products

WHY SHOP WITH US?

CLIENTS
ChemShuttle has served 800+ organizations worldwide with 80,000+ catalog compounds.

SCIENCE
Providing novel research molecules to clients in the most cost-effective way.

FACILITY
30,000-square-foot facility in Shanghai and Wuxi City, Jiangsu.

Catalog No.: T33972

CAS # 30569-44-6

Catalog No.: T39071

CAS # 153390-61-3

Catalog No.: T00982

CAS # 173200-25-6

Catalog No.: T33385

CAS # 19171-10-7

Catalog No.: T33091

CAS # 53035-61-1

Tel: +1 510.999.8905
Add: 1633 Old Bayshore Highway
Suite 280 Burlingame, CA 94010

Email: Sales@ChemShuttle.com
https://www.chemshuttle.com

江苏无锡 (惠山) 生命科技产业园
Wuxi Huishan Life Science & Technology Industrial Park (L-PARK)



Life science and technology industry is a high-end industry with intensive technology, capital and talents. After years of development, it has formed four major sectors: cell-based pharmaceuticals, medical device manufacturing, enterprise incubation, research and development, and health care services, mainly focusing on high-end innovative drugs, a base for intermediate production and medical device manufacturing represented by Apptec and BoDuro, building the industrial structure of integrating precision diagnosis and treatment, high-end medicine and medical equipment.

**JOIN HUIZHAN
CREATE THE FUTURE**



Huishan Economic Development Zone has established the development pattern of "Four parks, one base and two centers" in terms of industrial layout, and formed five leading industries, including automobile and parts, high-end equipment manufacturing, new energy and new materials, life science and technology, and new generation information technology, which have comparative advantages and leading advantages in information technology, which have comparative advantages and leading advantages.

01 Cutting-edge medical device industry
This industry is dominated by domestic leaders in the field of invisible correction such as Angalign and DEAFAC, leaders in global mouth grinding machine and dental implant like Shiyang of South Korea and Headman.

02 High-end biomedical industry
It gathers nasdaq-listed CASI Pharmaceutical and Sileman Biological. And Huatai Innovative Medicine Research Institute which is expected to become the first in China to successfully develop 11 new drugs. A complete innovation system for new drug development and clinical research has been established.

03 Cutting-edge precision medicine industry
Gathers a number of industrial leading institutes, including the Zhengze Precision Medicine Inspection Institute of Jiangsu's first precision medicine engineering center, ASGU which 60% market share of the domestic forensic DNA testing field, and Shennu Biology, an enterprise with the global patent of prostate early screening and Wuxi eye Laboratory, etc.

51

52



CHINESE AMERICAN BIO/ PHARMACEUTICAL SOCIETY



cabsweb.org

268 Bush Street
#1888, San Francisco
CA 94104, USA

GENERAL INFORMATION

Info@CABSweb.org

MEMBERSHIP

Membership@CABSweb.org

FUNDRAISING

Fundraising@CABSweb.org



[LinkedIn](#)



[Newsletter](#)



[CABS
main page](#)



[Member
Registration](#)